| Symbol | LXRX |
|---|---|
| Name | LEXICON PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2445 TECHNOLOGY FOREST BOULEVARD,11TH FLOOR, THE WOODLANDS, Texas, 77381, United States |
| Telephone | +1 281 863-3000 |
| Fax | — |
| — | |
| Website | https://www.lexpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001062822 |
| Description | Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Additional info from NASDAQ: |
2026-06-04 20:14
Director Swain Judith L 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000108
Read more
2026-06-04 20:13
Director Sullivan Diane E. 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000107
Read more
2026-06-04 20:13
Director SOBECKI CHRISTOPHER J 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000106
Read more
2026-06-04 20:12
Director Cheung Ivan 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000105
Read more
2026-06-04 20:11
Director BARKER SAM L 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000104
Read more
2026-06-04 20:10
Director Amouyal Philippe 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000103
Read more
2026-06-04 20:09
Director DEBBANE RAYMOND 🟡 adjusted position in 0 shares (1 derivative) of LEXICON PHARMACEUTICALS, INC. (LXRX) Transaction Date: Jun 03, 2026 | Filing ID: 000102
Read more
2026-06-03 12:00
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Read more
2026-05-28 12:30
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Read more
2026-05-12 12:30
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05982938 | Danicopan Early Access Program | — | Paroxysmal Nocturnal Hemoglobinuria | Available | — | — | ClinicalTrials.gov |
| NCT02376751 | An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Aci… | — | Lysosomal Acid Lipase Deficiency | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02496689 | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile… | — | Hypophosphatasia | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00438789 | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol | — | Hemoglobinuria, Paroxysmal | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT05686564 | Early Access Program for ALXN1840 in Patients With Wilson Disease | — | Wilson Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05686564 | Early Access Program for ALXN1840 in Patients With Wilson Disease | — | Wilson Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04802083 | COVID-19 Soliris Expanded Access Protocol | — | Covid19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00040157 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Ad… | Phase2 | HIV Infections | Terminated | — | 2003-05-01 | ClinicalTrials.gov |
| NCT04802083 | COVID-19 Soliris Expanded Access Protocol | — | Covid19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04757259 | Expanded Access Program for Participants Who Completed Study 13-601 and Continu… | — | Relapsed/Refractory Chronic Lymphocytic Leukemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00037622 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Ad… | Na | Chronic Hepatitis B | Terminated | — | 2003-05-01 | ClinicalTrials.gov |
| NCT05982938 | Danicopan Early Access Program | — | Paroxysmal Nocturnal Hemoglobinuria | Available | — | — | ClinicalTrials.gov |
| NCT04757259 | Expanded Access Program for Participants Who Completed Study 13-601 and Continu… | — | Relapsed/Refractory Chronic Lymphocytic Leukemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | — | COVID-19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | — | COVID-19 | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00438789 | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol | — | Hemoglobinuria, Paroxysmal | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT02496689 | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile… | — | Hypophosphatasia | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT02376751 | An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Aci… | — | Lysosomal Acid Lipase Deficiency | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00040157 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Ad… | Phase2 | HIV Infections | Terminated | — | 2003-05-01 | ClinicalTrials.gov |
| NCT00037622 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Ad… | Na | Chronic Hepatitis B | Terminated | — | 2003-05-01 | ClinicalTrials.gov |
| NCT07557420 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study … | Phase3 | NMOSD | Not_Yet_Recruiting | 2026-08-31 | 2028-10-31 | ClinicalTrials.gov |
| NCT07557420 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study … | Phase3 | NMOSD | Not_Yet_Recruiting | 2026-08-31 | 2028-10-31 | ClinicalTrials.gov |
| NCT07596784 | Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generali… | Phase3 | Generalized Myasthenia Gravis | Not_Yet_Recruiting | 2026-07-30 | 2027-08-27 | ClinicalTrials.gov |
| NCT07596784 | Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generali… | Phase3 | Generalized Myasthenia Gravis | Not_Yet_Recruiting | 2026-07-30 | 2027-08-27 | ClinicalTrials.gov |
| NCT06015750 | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSI… | Phase4 | Hypophosphatasia | Withdrawn | 2026-07-29 | 2030-03-13 | ClinicalTrials.gov |
| NCT06015750 | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSI… | Phase4 | Hypophosphatasia | Withdrawn | 2026-07-29 | 2030-03-13 | ClinicalTrials.gov |
| NCT07211802 | CKM For Safe Use of SGLT2i in Type 1 Diabetes | Phase3 | Type 1 Diabetes (T1D) | Not_Yet_Recruiting | 2026-07-01 | 2030-12-31 | ClinicalTrials.gov |
| NCT07211802 | CKM For Safe Use of SGLT2i in Type 1 Diabetes | Phase3 | Type 1 Diabetes (T1D) | Not_Yet_Recruiting | 2026-07-01 | 2030-12-31 | ClinicalTrials.gov |
| NCT07352423 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in… | Phase1 | Healthy Adult Participants | Recruiting | 2026-03-26 | 2026-12-23 | ClinicalTrials.gov |
| NCT07352423 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in… | Phase1 | Healthy Adult Participants | Recruiting | 2026-03-26 | 2026-12-23 | ClinicalTrials.gov |
| NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myas… | Phase4 | Generalized Myasthenia Gravis | Recruiting | 2026-03-04 | 2027-08-27 | ClinicalTrials.gov |
| NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myas… | Phase4 | Generalized Myasthenia Gravis | Recruiting | 2026-03-04 | 2027-08-27 | ClinicalTrials.gov |
| NCT07413250 | Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxy… | — | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2026-01-14 | 2030-01-15 | ClinicalTrials.gov |
| NCT07413250 | Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxy… | — | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2026-01-14 | 2030-01-15 | ClinicalTrials.gov |
| NCT07337395 | Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab | — | Myasthenia Gravis Generalised | Not_Yet_Recruiting | 2026-01-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT07337395 | Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab | — | Myasthenia Gravis Generalised | Not_Yet_Recruiting | 2026-01-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | Phase4 | aHUS | Recruiting | 2025-12-19 | 2027-06-25 | ClinicalTrials.gov |
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | Phase4 | aHUS | Recruiting | 2025-12-19 | 2027-06-25 | ClinicalTrials.gov |
| NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil … | Phase2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Recruiting | 2025-11-26 | 2028-02-14 | ClinicalTrials.gov |
| NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil … | Phase2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Recruiting | 2025-11-26 | 2028-02-14 | ClinicalTrials.gov |
| NCT07037420 | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participant… | Phase2 | Acromegaly | Recruiting | 2025-10-28 | 2027-11-11 | ClinicalTrials.gov |
| NCT07037420 | ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participant… | Phase2 | Acromegaly | Recruiting | 2025-10-28 | 2027-11-11 | ClinicalTrials.gov |
| NCT07218887 | ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | Phase1 | BAG3 Mutation Associated Dilated Cardiomyopathy | Recruiting | 2025-10-24 | 2032-01-27 | ClinicalTrials.gov |
| NCT07218887 | ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | Phase1 | BAG3 Mutation Associated Dilated Cardiomyopathy | Recruiting | 2025-10-24 | 2032-01-27 | ClinicalTrials.gov |
| NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Asso… | Phase4 | Transthyretin-type Cardiac Amyloidosis | Recruiting | 2025-10-01 | 2028-03-31 | ClinicalTrials.gov |
| NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Asso… | Phase4 | Transthyretin-type Cardiac Amyloidosis | Recruiting | 2025-10-01 | 2028-03-31 | ClinicalTrials.gov |
| NCT06933056 | Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatele… | Early_Phase1 | Platelet Function and Reactivity Tests | Recruiting | 2025-09-02 | 2026-09-01 | ClinicalTrials.gov |
| NCT06933056 | Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatele… | Early_Phase1 | Platelet Function and Reactivity Tests | Recruiting | 2025-09-02 | 2026-09-01 | ClinicalTrials.gov |
| NCT07213583 | Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Phase2 | Amyloid Transthyretin Cardiomyopathy | Active_Not_Recruiting | 2025-08-28 | 2026-10-31 | ClinicalTrials.gov |
| NCT07213583 | Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Phase2 | Amyloid Transthyretin Cardiomyopathy | Active_Not_Recruiting | 2025-08-28 | 2026-10-31 | ClinicalTrials.gov |
| NCT07413679 | Long-term Safety of Danicopan: IPIG Registry-based Cohort Study | — | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2025-08-18 | 2029-07-01 | ClinicalTrials.gov |
| NCT07413679 | Long-term Safety of Danicopan: IPIG Registry-based Cohort Study | — | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2025-08-18 | 2029-07-01 | ClinicalTrials.gov |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participant… | Phase1 | Relapsed AL Amyloidosis | Recruiting | 2025-08-18 | 2031-02-14 | ClinicalTrials.gov |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participant… | Phase1 | Relapsed AL Amyloidosis | Recruiting | 2025-08-18 | 2031-02-14 | ClinicalTrials.gov |
| NCT06449001 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatri… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 2025-08-11 | 2028-03-10 | ClinicalTrials.gov |
| NCT06449001 | Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatri… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Recruiting | 2025-08-11 | 2028-03-10 | ClinicalTrials.gov |
| NCT06967480 | Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthe… | — | Generalized Myasthenia Gravis | Recruiting | 2025-07-31 | 2027-06-30 | ClinicalTrials.gov |
| NCT06967480 | Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthe… | — | Generalized Myasthenia Gravis | Recruiting | 2025-07-31 | 2027-06-30 | ClinicalTrials.gov |
| NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | Phase3 | IgAN | Recruiting | 2025-06-14 | 2029-11-27 | ClinicalTrials.gov |
| NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | Phase3 | IgAN | Recruiting | 2025-06-14 | 2029-11-27 | ClinicalTrials.gov |
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the… | Phase3 | Delayed Graft Function | Recruiting | 2025-05-19 | 2028-08-30 | ClinicalTrials.gov |
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the… | Phase3 | Delayed Graft Function | Recruiting | 2025-05-19 | 2028-08-30 | ClinicalTrials.gov |
| NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Ki… | Phase2 | Antibody-Mediated Rejection | Recruiting | 2025-03-07 | 2028-11-07 | ClinicalTrials.gov |
| NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Ki… | Phase2 | Antibody-Mediated Rejection | Recruiting | 2025-03-07 | 2028-11-07 | ClinicalTrials.gov |
| NCT06435156 | Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes | Phase2 | Type 1 Diabetes | Recruiting | 2025-01-28 | 2027-10-31 | ClinicalTrials.gov |
| NCT06435156 | Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes | Phase2 | Type 1 Diabetes | Recruiting | 2025-01-28 | 2027-10-31 | ClinicalTrials.gov |
| NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | Phase3 | NMOSD | Active_Not_Recruiting | 2025-01-16 | 2026-12-07 | ClinicalTrials.gov |
| NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | Phase3 | NMOSD | Active_Not_Recruiting | 2025-01-16 | 2026-12-07 | ClinicalTrials.gov |
| NCT06764160 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ecu… | Phase3 | Generalized Myasthenia Gravis (gMG) | Completed | 2025-01-06 | 2025-12-29 | ClinicalTrials.gov |
| NCT06764160 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ecu… | Phase3 | Generalized Myasthenia Gravis (gMG) | Completed | 2025-01-06 | 2025-12-29 | ClinicalTrials.gov |
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | — | Ultomiris-exposed Pregnant/ Postpartum | Recruiting | 2024-12-16 | 2034-07-11 | ClinicalTrials.gov |
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | — | Ultomiris-exposed Pregnant/ Postpartum | Recruiting | 2024-12-16 | 2034-07-11 | ClinicalTrials.gov |
| NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AC… | Phase3 | Generalized Myasthenia Gravis | Recruiting | 2024-11-13 | 2029-01-23 | ClinicalTrials.gov |
| NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AC… | Phase3 | Generalized Myasthenia Gravis | Recruiting | 2024-11-13 | 2029-01-23 | ClinicalTrials.gov |
| NCT06374264 | Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spect… | Na | Neuromyelitis Optica Spectrum Disorder | Enrolling_By_Invitation | 2024-11-12 | 2026-03-31 | ClinicalTrials.gov |
| NCT06374264 | Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spect… | Na | Neuromyelitis Optica Spectrum Disorder | Enrolling_By_Invitation | 2024-11-12 | 2026-03-31 | ClinicalTrials.gov |
| NCT06677138 | PK Study of Gefurulimab SC in Healthy Chinese Adult Participants | Phase1 | Healthy | Completed | 2024-10-28 | 2025-03-19 | ClinicalTrials.gov |
| NCT06677138 | PK Study of Gefurulimab SC in Healthy Chinese Adult Participants | Phase1 | Healthy | Completed | 2024-10-28 | 2025-03-19 | ClinicalTrials.gov |
| NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Rav… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2024-10-10 | 2025-12-22 | ClinicalTrials.gov |
| NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Rav… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2024-10-10 | 2025-12-22 | ClinicalTrials.gov |
| NCT06481891 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obs… | Phase3 | Obstructive Cardiomyopathy, Hypertrophic | Recruiting | 2024-09-24 | 2026-08-01 | ClinicalTrials.gov |
| NCT06481891 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obs… | Phase3 | Obstructive Cardiomyopathy, Hypertrophic | Recruiting | 2024-09-24 | 2026-08-01 | ClinicalTrials.gov |
| NCT05696366 | Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type… | Phase1 | Type 1 Diabetes | Active_Not_Recruiting | 2024-09-09 | 2028-01-01 | ClinicalTrials.gov |
| NCT05696366 | Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type… | Phase1 | Type 1 Diabetes | Active_Not_Recruiting | 2024-09-09 | 2028-01-01 | ClinicalTrials.gov |
| NCT06398158 | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neu… | — | Neuromyelitis Optica | Recruiting | 2024-07-10 | 2027-06-30 | ClinicalTrials.gov |
| NCT06398158 | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neu… | — | Neuromyelitis Optica | Recruiting | 2024-07-10 | 2027-06-30 | ClinicalTrials.gov |
| NCT06079359 | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | Phase3 | Hypophosphatasia | Active_Not_Recruiting | 2024-05-14 | 2028-08-24 | ClinicalTrials.gov |
| NCT06079359 | Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP | Phase3 | Hypophosphatasia | Active_Not_Recruiting | 2024-05-14 | 2028-08-24 | ClinicalTrials.gov |
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated… | Phase3 | Hypophosphatasia | Active_Not_Recruiting | 2024-04-02 | 2028-02-29 | ClinicalTrials.gov |
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated… | Phase3 | Hypophosphatasia | Active_Not_Recruiting | 2024-04-02 | 2028-02-29 | ClinicalTrials.gov |
| NCT06291376 | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Phase3 | Immunoglobulin A Nephropathy | Active_Not_Recruiting | 2024-03-29 | 2030-07-19 | ClinicalTrials.gov |
| NCT06291376 | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Phase3 | Immunoglobulin A Nephropathy | Active_Not_Recruiting | 2024-03-29 | 2030-07-19 | ClinicalTrials.gov |
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapi… | — | Neuromyelitis Optica Spectrum Disorder | Recruiting | 2024-02-01 | 2029-09-27 | ClinicalTrials.gov |
| NCT05966467 | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapi… | — | Neuromyelitis Optica Spectrum Disorder | Recruiting | 2024-02-01 | 2029-09-27 | ClinicalTrials.gov |
| NCT06071442 | Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin… | Phase1 | Healthy Participants | Completed | 2024-01-17 | 2024-04-12 | ClinicalTrials.gov |
| NCT06071442 | Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin… | Phase1 | Healthy Participants | Completed | 2024-01-17 | 2024-04-12 | ClinicalTrials.gov |
| NCT06183931 | Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | Phase3 | Transthyretin Amyloid Cardiomyopathy | Active_Not_Recruiting | 2024-01-11 | 2027-10-05 | ClinicalTrials.gov |
| NCT06183931 | Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | Phase3 | Transthyretin Amyloid Cardiomyopathy | Active_Not_Recruiting | 2024-01-11 | 2027-10-05 | ClinicalTrials.gov |
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazo… | Phase1 | Healthy | Completed | 2024-01-10 | 2024-05-16 | ClinicalTrials.gov |
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazo… | Phase1 | Healthy | Completed | 2024-01-10 | 2024-05-16 | ClinicalTrials.gov |
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants W… | Phase3 | Hypophosphatasia | Active_Not_Recruiting | 2024-01-03 | 2028-03-29 | ClinicalTrials.gov |
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants W… | Phase3 | Hypophosphatasia | Active_Not_Recruiting | 2024-01-03 | 2028-03-29 | ClinicalTrials.gov |
| NCT06203002 | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPN… | Phase2 | Diabetic Peripheral Neuropathic Pain | Completed | 2023-11-29 | 2025-02-24 | ClinicalTrials.gov |
| NCT06203002 | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPN… | Phase2 | Diabetic Peripheral Neuropathic Pain | Completed | 2023-11-29 | 2025-02-24 | ClinicalTrials.gov |
| NCT06208488 | A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector… | Phase1 | Healthy Adult Participants | Completed | 2023-11-22 | 2024-09-28 | ClinicalTrials.gov |
| NCT06208488 | A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector… | Phase1 | Healthy Adult Participants | Completed | 2023-11-22 | 2024-09-28 | ClinicalTrials.gov |
| NCT05840055 | ACT with NMOSD Patients and Caregivers Pilot Study | Na | NMO Spectrum Disorder | Completed | 2023-08-01 | 2024-11-21 | ClinicalTrials.gov |
| NCT05840055 | ACT with NMOSD Patients and Caregivers Pilot Study | Na | NMO Spectrum Disorder | Completed | 2023-08-01 | 2024-11-21 | ClinicalTrials.gov |
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic S… | Phase3 | Atypical Hemolytic Uremic | Completed | 2023-07-14 | 2025-05-07 | ClinicalTrials.gov |
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic S… | Phase3 | Atypical Hemolytic Uremic | Completed | 2023-07-14 | 2025-05-07 | ClinicalTrials.gov |
| NCT05644561 | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in… | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2023-06-24 | 2028-06-30 | ClinicalTrials.gov |
| NCT05644561 | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in… | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2023-06-24 | 2028-06-30 | ClinicalTrials.gov |
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients W… | Phase3 | Chronic Hypoparathyroidism | Active_Not_Recruiting | 2023-06-07 | 2027-06-16 | ClinicalTrials.gov |
| NCT05778071 | Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients W… | Phase3 | Chronic Hypoparathyroidism | Active_Not_Recruiting | 2023-06-07 | 2027-06-16 | ClinicalTrials.gov |
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920… | Phase1 | Healthy Participants | Completed | 2023-04-19 | 2023-12-04 | ClinicalTrials.gov |
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920… | Phase1 | Healthy Participants | Completed | 2023-04-19 | 2023-12-04 | ClinicalTrials.gov |
| NCT06160414 | A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Ros… | Phase1 | Healthy | Completed | 2023-04-12 | 2024-02-05 | ClinicalTrials.gov |
| NCT06160414 | A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Ros… | Phase1 | Healthy | Completed | 2023-04-12 | 2024-02-05 | ClinicalTrials.gov |
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | Phase3 | Chronic Kidney Disease | Completed | 2023-04-06 | 2026-05-07 | ClinicalTrials.gov |
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | Phase3 | Chronic Kidney Disease | Completed | 2023-04-06 | 2026-05-07 | ClinicalTrials.gov |
| NCT05780645 | A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release… | Phase1 | Healthy Participants | Completed | 2023-03-15 | 2024-02-26 | ClinicalTrials.gov |
| NCT05780645 | A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release… | Phase1 | Healthy Participants | Completed | 2023-03-15 | 2024-02-26 | ClinicalTrials.gov |
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adu… | Phase2 | Sickle Cell Disease (SCD) | Terminated | 2023-02-22 | 2024-01-09 | ClinicalTrials.gov |
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adu… | Phase2 | Sickle Cell Disease (SCD) | Terminated | 2023-02-22 | 2024-01-09 | ClinicalTrials.gov |
| NCT05708573 | Potential Drug Interaction Between ALXN2040 and Rosuvastatin | Phase1 | Healthy Participants | Completed | 2023-02-01 | 2023-04-05 | ClinicalTrials.gov |
| NCT05708573 | Potential Drug Interaction Between ALXN2040 and Rosuvastatin | Phase1 | Healthy Participants | Completed | 2023-02-01 | 2023-04-05 | ClinicalTrials.gov |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2022-11-21 | 2027-08-31 | ClinicalTrials.gov |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | Phase3 | Generalized Myasthenia Gravis | Active_Not_Recruiting | 2022-11-21 | 2027-08-31 | ClinicalTrials.gov |
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Comp… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2022-10-28 | 2026-08-24 | ClinicalTrials.gov |
| NCT05389449 | A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Comp… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Active_Not_Recruiting | 2022-10-28 | 2026-08-24 | ClinicalTrials.gov |
| NCT05981092 | A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a… | — | Cardiomyopathy, Dilated | Active_Not_Recruiting | 2022-10-14 | 2027-08-12 | ClinicalTrials.gov |
| NCT05981092 | A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a… | — | Cardiomyopathy, Dilated | Active_Not_Recruiting | 2022-10-14 | 2027-08-12 | ClinicalTrials.gov |
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALX… | Phase1 | Healthy Adult Participants | Completed | 2022-10-13 | 2023-01-05 | ClinicalTrials.gov |
| NCT05578846 | Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALX… | Phase1 | Healthy Adult Participants | Completed | 2022-10-13 | 2023-01-05 | ClinicalTrials.gov |
| NCT05428696 | Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses… | Phase1 | Healthy | Completed | 2022-09-12 | 2023-05-26 | ClinicalTrials.gov |
| NCT05428696 | Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses… | Phase1 | Healthy | Completed | 2022-09-12 | 2023-05-26 | ClinicalTrials.gov |
| NCT05234567 | A Prospective Sub-Study of the Global Hypophosphatasia Registry | — | Hypophosphatasia | Recruiting | 2022-08-25 | 2028-07-18 | ClinicalTrials.gov |
| NCT05234567 | A Prospective Sub-Study of the Global Hypophosphatasia Registry | — | Hypophosphatasia | Recruiting | 2022-08-25 | 2028-07-18 | ClinicalTrials.gov |
| NCT05501717 | Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants | Phase1 | Healthy | Active_Not_Recruiting | 2022-08-16 | 2026-10-14 | ClinicalTrials.gov |
| NCT05501717 | Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants | Phase1 | Healthy | Active_Not_Recruiting | 2022-08-16 | 2026-10-14 | ClinicalTrials.gov |
| NCT05506254 | Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy | — | Methylmalonic Acidemia | Active_Not_Recruiting | 2022-07-15 | 2037-01-01 | ClinicalTrials.gov |
| NCT05506254 | Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy | — | Methylmalonic Acidemia | Active_Not_Recruiting | 2022-07-15 | 2037-01-01 | ClinicalTrials.gov |
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With … | Phase1 | Proteinuria | Completed | 2022-06-29 | 2023-05-31 | ClinicalTrials.gov |
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With … | Phase1 | Proteinuria | Completed | 2022-06-29 | 2023-05-31 | ClinicalTrials.gov |
| NCT05346354 | Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD | Phase2 | Neuromyelitis Optica Spectrum Disorder | Active_Not_Recruiting | 2022-06-23 | 2029-03-30 | ClinicalTrials.gov |
| NCT05346354 | Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD | Phase2 | Neuromyelitis Optica Spectrum Disorder | Active_Not_Recruiting | 2022-06-23 | 2029-03-30 | ClinicalTrials.gov |
| NCT05274633 | Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemo… | — | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2022-06-17 | 2025-03-24 | ClinicalTrials.gov |
| NCT05274633 | Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemo… | — | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2022-06-17 | 2025-03-24 | ClinicalTrials.gov |
| NCT05218096 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | Phase2 | Generalized Myasthenia Gravis | Terminated | 2022-04-27 | 2024-04-03 | ClinicalTrials.gov |
| NCT05218096 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | Phase2 | Generalized Myasthenia Gravis | Terminated | 2022-04-27 | 2024-04-03 | ClinicalTrials.gov |
| NCT05307978 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910… | Phase1 | Healthy | Completed | 2022-04-12 | 2023-02-07 | ClinicalTrials.gov |
| NCT05307978 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910… | Phase1 | Healthy | Completed | 2022-04-12 | 2023-02-07 | ClinicalTrials.gov |
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | Phase1 | Impaired Hepatic Function | Terminated | 2022-04-07 | 2024-08-12 | ClinicalTrials.gov |
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | Phase1 | Impaired Hepatic Function | Terminated | 2022-04-07 | 2024-08-12 | ClinicalTrials.gov |
| NCT05419765 | Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease | — | Non-Alcoholic Fatty Liver Disease | Completed | 2022-03-01 | 2023-03-31 | ClinicalTrials.gov |
| NCT05419765 | Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease | — | Non-Alcoholic Fatty Liver Disease | Completed | 2022-03-01 | 2023-03-31 | ClinicalTrials.gov |
| NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nep… | Phase2 | Lupus Nephritis | Terminated | 2022-01-14 | 2024-12-09 | ClinicalTrials.gov |
| NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nep… | Phase2 | Lupus Nephritis | Terminated | 2022-01-14 | 2024-12-09 | ClinicalTrials.gov |
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2022-01-11 | 2022-03-21 | ClinicalTrials.gov |
| NCT05202145 | Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2022-01-11 | 2022-03-21 | ClinicalTrials.gov |
| NCT04982289 | Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasth… | Phase2 | Generalized Myasthenia Gravis | Withdrawn | 2022-01-01 | 2024-01-31 | ClinicalTrials.gov |
| NCT04956276 | Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anem… | Phase2 | Warm Autoimmune Hemolytic Anemia | Withdrawn | 2022-01-01 | 2024-07-31 | ClinicalTrials.gov |
| NCT04956276 | Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anem… | Phase2 | Warm Autoimmune Hemolytic Anemia | Withdrawn | 2022-01-01 | 2024-07-31 | ClinicalTrials.gov |
| NCT04982289 | Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasth… | Phase2 | Generalized Myasthenia Gravis | Withdrawn | 2022-01-01 | 2024-01-31 | ClinicalTrials.gov |
| NCT04999020 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | Phase2 | Dermatomyositis | Terminated | 2021-11-19 | 2024-05-08 | ClinicalTrials.gov |
| NCT04999020 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | Phase2 | Dermatomyositis | Terminated | 2021-11-19 | 2024-05-08 | ClinicalTrials.gov |
| NCT03468140 | Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macros… | Early_Phase1 | End Stage Liver Disease | Withdrawn | 2021-10-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT03468140 | Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macros… | Early_Phase1 | End Stage Liver Disease | Withdrawn | 2021-10-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04980248 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | Phase1 | Hypophosphatasia | Completed | 2021-09-28 | 2022-08-24 | ClinicalTrials.gov |
| NCT04980248 | Study of ALXN1850 in Participants With Hypophosphatasia (HPP) | Phase1 | Hypophosphatasia | Completed | 2021-09-28 | 2022-08-24 | ClinicalTrials.gov |
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson… | Phase3 | Wilson Disease | Terminated | 2021-09-13 | 2023-06-26 | ClinicalTrials.gov |
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson… | Phase3 | Wilson Disease | Terminated | 2021-09-13 | 2023-06-26 | ClinicalTrials.gov |
| NCT04725812 | Complement Regulation to Undo Systemic Harm in Preeclampsia | Phase2 | Preeclampsia | Terminated | 2021-09-13 | 2021-12-07 | ClinicalTrials.gov |
| NCT04725812 | Complement Regulation to Undo Systemic Harm in Preeclampsia | Phase2 | Preeclampsia | Terminated | 2021-09-13 | 2021-12-07 | ClinicalTrials.gov |
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-R… | Phase2 | Geographic Atrophy | Terminated | 2021-08-23 | 2025-01-21 | ClinicalTrials.gov |
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-R… | Phase2 | Geographic Atrophy | Terminated | 2021-08-23 | 2025-01-21 | ClinicalTrials.gov |
| NCT04970004 | Study in Adult and Pediatric Patients With HSCT-TMA | — | Stem Cell Transplant Complications | Withdrawn | 2021-07-12 | 2022-04-01 | ClinicalTrials.gov |
| NCT04970004 | Study in Adult and Pediatric Patients With HSCT-TMA | — | Stem Cell Transplant Complications | Withdrawn | 2021-07-12 | 2022-04-01 | ClinicalTrials.gov |
| NCT04952545 | Study of ALXN2050 in Healthy Adult Participants of Japanese Descent | Phase1 | Healthy | Completed | 2021-07-09 | 2021-09-07 | ClinicalTrials.gov |
| NCT04952545 | Study of ALXN2050 in Healthy Adult Participants of Japanese Descent | Phase1 | Healthy | Completed | 2021-07-09 | 2021-09-07 | ClinicalTrials.gov |
| NCT04623710 | Study of ALXN2050 in Participants With Renal Impairment | Phase1 | Renal Impairment | Completed | 2021-07-08 | 2022-03-21 | ClinicalTrials.gov |
| NCT04623710 | Study of ALXN2050 in Participants With Renal Impairment | Phase1 | Renal Impairment | Completed | 2021-07-08 | 2022-03-21 | ClinicalTrials.gov |
| NCT04256148 | ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia | Phase2 | Warm Autoimmune Hemolytic Anemia | Withdrawn | 2021-07-01 | 2023-04-30 | ClinicalTrials.gov |
| NCT04256148 | ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia | Phase2 | Warm Autoimmune Hemolytic Anemia | Withdrawn | 2021-07-01 | 2023-04-30 | ClinicalTrials.gov |
| NCT04743804 | Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger | Phase3 | Thrombotic Microangiopathy | Terminated | 2021-06-29 | 2022-12-22 | ClinicalTrials.gov |
| NCT04743804 | Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger | Phase3 | Thrombotic Microangiopathy | Terminated | 2021-06-29 | 2022-12-22 | ClinicalTrials.gov |
| NCT04233073 | Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urge… | Phase2 | Surgery | Terminated | 2021-06-27 | 2022-01-25 | ClinicalTrials.gov |
| NCT04233073 | Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urge… | Phase2 | Surgery | Terminated | 2021-06-27 | 2022-01-25 | ClinicalTrials.gov |
| NCT04933682 | Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adu… | Phase1 | Healthy | Completed | 2021-06-23 | 2021-08-04 | ClinicalTrials.gov |
| NCT04933682 | Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adu… | Phase1 | Healthy | Completed | 2021-06-23 | 2021-08-04 | ClinicalTrials.gov |
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | — | Hypophosphatasia | Completed | 2021-06-02 | 2021-12-02 | ClinicalTrials.gov |
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | — | Hypophosphatasia | Completed | 2021-06-02 | 2021-12-02 | ClinicalTrials.gov |
| NCT04958135 | Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Ad… | Phase1 | Healthy | Completed | 2021-05-30 | 2021-08-04 | ClinicalTrials.gov |
| NCT04958135 | Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Ad… | Phase1 | Healthy | Completed | 2021-05-30 | 2021-08-04 | ClinicalTrials.gov |
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acide… | Phase1 | Methylmalonic Acidemia | Terminated | 2021-05-29 | 2023-01-10 | ClinicalTrials.gov |
| NCT04581785 | Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acide… | Phase1 | Methylmalonic Acidemia | Terminated | 2021-05-29 | 2023-01-10 | ClinicalTrials.gov |
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | — | Acid Sphingomyelinase Deficiency | Enrolling_By_Invitation | 2021-05-10 | 2029-08-31 | ClinicalTrials.gov |
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | — | Acid Sphingomyelinase Deficiency | Enrolling_By_Invitation | 2021-05-10 | 2029-08-31 | ClinicalTrials.gov |
| NCT04320602 | Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Curr… | Phase4 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2021-04-14 | 2022-12-20 | ClinicalTrials.gov |
| NCT04320602 | Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Curr… | Phase4 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2021-04-14 | 2022-12-20 | ClinicalTrials.gov |
| NCT04609670 | Study of Radiolabeled ALXN2050 in Healthy Adult Males | Phase1 | Healthy | Completed | 2021-04-12 | 2021-08-23 | ClinicalTrials.gov |
| NCT04609670 | Study of Radiolabeled ALXN2050 in Healthy Adult Males | Phase1 | Healthy | Completed | 2021-04-12 | 2021-08-23 | ClinicalTrials.gov |
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | Phase1 | Healthy | Terminated | 2021-03-17 | 2022-01-04 | ClinicalTrials.gov |
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | Phase1 | Healthy | Terminated | 2021-03-17 | 2022-01-04 | ClinicalTrials.gov |
| NCT04752566 | A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syn… | Phase3 | Guillain-Barre Syndrome | Completed | 2021-03-08 | 2022-08-03 | ClinicalTrials.gov |
| NCT04752566 | A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syn… | Phase3 | Guillain-Barre Syndrome | Completed | 2021-03-08 | 2022-08-03 | ClinicalTrials.gov |
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 | Phase1 | Healthy | Completed | 2021-01-31 | 2021-04-26 | ClinicalTrials.gov |
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 | Phase1 | Healthy | Completed | 2021-01-31 | 2021-04-26 | ClinicalTrials.gov |
| NCT04564339 | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A … | Phase2 | Lupus Nephritis | Terminated | 2021-01-19 | 2025-08-18 | ClinicalTrials.gov |
| NCT04564339 | Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A … | Phase2 | Lupus Nephritis | Terminated | 2021-01-19 | 2025-08-18 | ClinicalTrials.gov |
| NCT04631562 | Study of ALXN1820 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2021-01-13 | 2022-09-01 | ClinicalTrials.gov |
| NCT04631562 | Study of ALXN1820 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2021-01-13 | 2022-09-01 | ClinicalTrials.gov |
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobi… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2020-12-16 | 2024-01-16 | ClinicalTrials.gov |
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobi… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2020-12-16 | 2024-01-16 | ClinicalTrials.gov |
| NCT04660890 | A Study of the Cardiac Effects of ALXN2050 in Healthy Adults | Phase1 | Healthy | Completed | 2020-12-12 | 2021-03-16 | ClinicalTrials.gov |
| NCT04660890 | A Study of the Cardiac Effects of ALXN2050 in Healthy Adults | Phase1 | Healthy | Completed | 2020-12-12 | 2021-03-16 | ClinicalTrials.gov |
| NCT04543591 | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transpl… | Phase3 | Thrombotic Microangiopathy | Completed | 2020-12-10 | 2026-03-20 | ClinicalTrials.gov |
| NCT04662281 | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | Phase2 | Postherpetic Neuralgia | Completed | 2020-12-10 | 2022-12-28 | ClinicalTrials.gov |
| NCT04662281 | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | Phase2 | Postherpetic Neuralgia | Completed | 2020-12-10 | 2022-12-28 | ClinicalTrials.gov |
| NCT04543591 | Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transpl… | Phase3 | Thrombotic Microangiopathy | Completed | 2020-12-10 | 2026-03-20 | ClinicalTrials.gov |
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | Phase3 | Thrombotic Microangiopathy | Completed | 2020-12-07 | 2025-05-27 | ClinicalTrials.gov |
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | Phase3 | Thrombotic Microangiopathy | Completed | 2020-12-07 | 2025-05-27 | ClinicalTrials.gov |
| NCT04422431 | Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants … | Phase2 | Wilson Disease | Completed | 2020-12-02 | 2023-05-17 | ClinicalTrials.gov |
| NCT04422431 | Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants … | Phase2 | Wilson Disease | Completed | 2020-12-02 | 2023-05-17 | ClinicalTrials.gov |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo S… | Phase3 | AL Amyloidosis | Active_Not_Recruiting | 2020-11-03 | 2027-04-08 | ClinicalTrials.gov |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo S… | Phase3 | AL Amyloidosis | Active_Not_Recruiting | 2020-11-03 | 2027-04-08 | ClinicalTrials.gov |
| NCT04526210 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participan… | Phase1 | Wilson Disease | Completed | 2020-10-21 | 2021-05-28 | ClinicalTrials.gov |
| NCT04526210 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participan… | Phase1 | Wilson Disease | Completed | 2020-10-21 | 2021-05-28 | ClinicalTrials.gov |
| NCT04609696 | Study of the Metabolism of Danicopan in Healthy Adults | Phase1 | Healthy | Completed | 2020-10-20 | 2020-12-07 | ClinicalTrials.gov |
| NCT04609696 | Study of the Metabolism of Danicopan in Healthy Adults | Phase1 | Healthy | Completed | 2020-10-20 | 2020-12-07 | ClinicalTrials.gov |
| NCT04034745 | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulatio… | — | Pancreatic Cancer | Withdrawn | 2020-10-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT04034745 | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulatio… | — | Pancreatic Cancer | Withdrawn | 2020-10-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT05239221 | AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroi… | Phase1 | Chronic Hypoparathyroidism | Completed | 2020-09-07 | 2022-08-23 | ClinicalTrials.gov |
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With … | Phase2 | Wilson Disease | Completed | 2020-09-07 | 2022-06-07 | ClinicalTrials.gov |
| NCT05239221 | AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroi… | Phase1 | Chronic Hypoparathyroidism | Completed | 2020-09-07 | 2022-08-23 | ClinicalTrials.gov |
| NCT04573309 | Copper and Molybdenum Balance in Participants With Wilson Disease Treated With … | Phase2 | Wilson Disease | Completed | 2020-09-07 | 2022-06-07 | ClinicalTrials.gov |
| NCT04455633 | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neu… | Phase2 | Diabetic Peripheral Neuropathy | Completed | 2020-09-03 | 2022-06-28 | ClinicalTrials.gov |
| NCT04455633 | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neu… | Phase2 | Diabetic Peripheral Neuropathy | Completed | 2020-09-03 | 2022-06-28 | ClinicalTrials.gov |
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo S… | Phase3 | AL Amyloidosis | Active_Not_Recruiting | 2020-08-25 | 2027-10-22 | ClinicalTrials.gov |
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo S… | Phase3 | AL Amyloidosis | Active_Not_Recruiting | 2020-08-25 | 2027-10-22 | ClinicalTrials.gov |
| NCT04451434 | Study of Danicopan in Participants of Japanese Descent | Phase1 | Healthy | Completed | 2020-08-17 | 2020-09-28 | ClinicalTrials.gov |
| NCT04451434 | Study of Danicopan in Participants of Japanese Descent | Phase1 | Healthy | Completed | 2020-08-17 | 2020-09-28 | ClinicalTrials.gov |
| NCT04560816 | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | Phase1 | Healthy | Completed | 2020-07-24 | 2021-03-24 | ClinicalTrials.gov |
| NCT04560816 | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | Phase1 | Healthy | Completed | 2020-07-24 | 2021-03-24 | ClinicalTrials.gov |
| NCT04526197 | Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Pa… | Phase1 | Wilson Disease | Completed | 2020-07-07 | 2020-11-03 | ClinicalTrials.gov |
| NCT04526197 | Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Pa… | Phase1 | Wilson Disease | Completed | 2020-07-07 | 2020-11-03 | ClinicalTrials.gov |
| NCT04594252 | Copper Balance in Healthy Participants Administered ALXN1840 | Phase1 | Healthy | Completed | 2020-07-01 | 2020-11-18 | ClinicalTrials.gov |
| NCT04594252 | Copper Balance in Healthy Participants Administered ALXN1840 | Phase1 | Healthy | Completed | 2020-07-01 | 2020-11-18 | ClinicalTrials.gov |
| NCT04551586 | A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Ver… | Phase1 | Healthy | Completed | 2020-06-26 | 2020-10-19 | ClinicalTrials.gov |
| NCT04551586 | A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Ver… | Phase1 | Healthy | Completed | 2020-06-26 | 2020-10-19 | ClinicalTrials.gov |
| NCT04369469 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pn… | Phase3 | COVID-19 Severe Pneumonia | Terminated | 2020-05-10 | 2021-04-08 | ClinicalTrials.gov |
| NCT04369469 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pn… | Phase3 | COVID-19 Severe Pneumonia | Terminated | 2020-05-10 | 2021-04-08 | ClinicalTrials.gov |
| NCT04189315 | Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due t… | Phase4 | Hypophosphatasia | Withdrawn | 2020-04-01 | 2022-08-01 | ClinicalTrials.gov |
| NCT04189315 | Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due t… | Phase4 | Hypophosphatasia | Withdrawn | 2020-04-01 | 2022-08-01 | ClinicalTrials.gov |
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | Phase3 | Amyotrophic Lateral Sclerosis | Terminated | 2020-03-30 | 2021-10-17 | ClinicalTrials.gov |
| NCT04248465 | An Efficacy and Safety Study of Ravulizumab in ALS Participants | Phase3 | Amyotrophic Lateral Sclerosis | Terminated | 2020-03-30 | 2021-10-17 | ClinicalTrials.gov |
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL… | Phase2 | AL Amyloidosis | Completed | 2020-03-18 | 2023-11-14 | ClinicalTrials.gov |
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL… | Phase2 | AL Amyloidosis | Completed | 2020-03-18 | 2023-11-14 | ClinicalTrials.gov |
| NCT04551599 | A Study of the Effects of Food and Age on Danicopan | Phase1 | Healthy | Completed | 2020-02-21 | 2021-02-03 | ClinicalTrials.gov |
| NCT04551599 | A Study of the Effects of Food and Age on Danicopan | Phase1 | Healthy | Completed | 2020-02-21 | 2021-02-03 | ClinicalTrials.gov |
| NCT04155424 | A Study of the Safety and Activity of Eculizumab in Pediatric Participants With… | Phase2 | Neuromyelitis Optica | Terminated | 2020-01-14 | 2023-07-31 | ClinicalTrials.gov |
| NCT04155424 | A Study of the Safety and Activity of Eculizumab in Pediatric Participants With… | Phase2 | Neuromyelitis Optica | Terminated | 2020-01-14 | 2023-07-31 | ClinicalTrials.gov |
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | Phase1 | Healthy | Completed | 2019-12-22 | 2020-04-16 | ClinicalTrials.gov |
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | Phase1 | Healthy | Completed | 2019-12-22 | 2020-04-16 | ClinicalTrials.gov |
| NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monothera… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Terminated | 2019-12-16 | 2024-03-20 | ClinicalTrials.gov |
| NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monothera… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Terminated | 2019-12-16 | 2024-03-20 | ClinicalTrials.gov |
| NCT04201262 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | Phase3 | Neuromyelitis Optica | Completed | 2019-12-09 | 2024-10-31 | ClinicalTrials.gov |
| NCT04201262 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | Phase3 | Neuromyelitis Optica | Completed | 2019-12-09 | 2024-10-31 | ClinicalTrials.gov |
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexio… | — | Generalized Myasthenia Gravis | Recruiting | 2019-12-02 | 2029-10-01 | ClinicalTrials.gov |
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexio… | — | Generalized Myasthenia Gravis | Recruiting | 2019-12-02 | 2029-10-01 | ClinicalTrials.gov |
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participan… | Phase1 | Healthy | Terminated | 2019-11-12 | 2021-01-22 | ClinicalTrials.gov |
| NCT05254613 | A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participan… | Phase1 | Healthy | Terminated | 2019-11-12 | 2021-01-22 | ClinicalTrials.gov |
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treat… | — | Hypophosphatasia | Completed | 2019-11-06 | 2024-04-12 | ClinicalTrials.gov |
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treat… | — | Hypophosphatasia | Completed | 2019-11-06 | 2024-04-12 | ClinicalTrials.gov |
| NCT04920370 | Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Heal… | Phase1 | Healthy | Completed | 2019-09-04 | 2021-11-16 | ClinicalTrials.gov |
| NCT04920370 | Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Heal… | Phase1 | Healthy | Completed | 2019-09-04 | 2021-11-16 | ClinicalTrials.gov |
| NCT04709094 | A Drug Interaction Study of Danicopan | Phase1 | Healthy | Completed | 2019-07-28 | 2020-04-17 | ClinicalTrials.gov |
| NCT04709094 | A Drug Interaction Study of Danicopan | Phase1 | Healthy | Completed | 2019-07-28 | 2020-04-17 | ClinicalTrials.gov |
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | Phase1 | Healthy | Completed | 2019-07-04 | 2019-10-09 | ClinicalTrials.gov |
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | Phase1 | Healthy | Completed | 2019-07-04 | 2019-10-09 | ClinicalTrials.gov |
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor | Phase4 | Acute Intracranial Hemorrhage | Completed | 2019-06-06 | 2023-08-09 | ClinicalTrials.gov |
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor | Phase4 | Acute Intracranial Hemorrhage | Completed | 2019-06-06 | 2023-08-09 | ClinicalTrials.gov |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage P… | Phase2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Completed | 2019-04-17 | 2022-06-29 | ClinicalTrials.gov |
| NCT03910387 | Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage P… | Phase2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Completed | 2019-04-17 | 2022-06-29 | ClinicalTrials.gov |
| NCT03920293 | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia … | Phase3 | Generalized Myasthenia Gravis | Completed | 2019-03-12 | 2023-05-25 | ClinicalTrials.gov |
| NCT03920293 | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia … | Phase3 | Generalized Myasthenia Gravis | Completed | 2019-03-12 | 2023-05-25 | ClinicalTrials.gov |
| NCT05641311 | Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healt… | Phase1 | Wilson Disease | Completed | 2019-02-20 | 2019-05-02 | ClinicalTrials.gov |
| NCT05641311 | Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healt… | Phase1 | Wilson Disease | Completed | 2019-02-20 | 2019-05-02 | ClinicalTrials.gov |
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults Wit… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2019-02-19 | 2023-08-31 | ClinicalTrials.gov |
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults Wit… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2019-02-19 | 2023-08-31 | ClinicalTrials.gov |
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | Phase1 | Healthy | Completed | 2019-01-07 | 2019-07-23 | ClinicalTrials.gov |
| NCT05047484 | A Study of Multiple Doses of ALXN2050 in Healthy Adults | Phase1 | Healthy | Completed | 2019-01-07 | 2019-07-23 | ClinicalTrials.gov |
| NCT05683678 | US Selumetinib Registry | — | Neurofibromatosis Type 1 | Terminated | 2019-01-04 | 2024-11-13 | ClinicalTrials.gov |
| NCT05683678 | US Selumetinib Registry | — | Neurofibromatosis Type 1 | Terminated | 2019-01-04 | 2024-11-13 | ClinicalTrials.gov |
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refract… | Phase3 | Myasthenia Gravis | Completed | 2018-12-28 | 2023-11-06 | ClinicalTrials.gov |
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refract… | Phase3 | Myasthenia Gravis | Completed | 2018-12-28 | 2023-11-06 | ClinicalTrials.gov |
| NCT03723512 | Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-co… | Na | C3 Glomerulonephritis | Completed | 2018-12-06 | 2021-02-17 | ClinicalTrials.gov |
| NCT03723512 | Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-co… | Na | C3 Glomerulonephritis | Completed | 2018-12-06 | 2021-02-17 | ClinicalTrials.gov |
| NCT03329365 | Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS | — | Paroxysmal Nocturnal Hemoglobinuria | Unknown | 2018-11-01 | 2025-03-29 | ClinicalTrials.gov |
| NCT03329365 | Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS | — | Paroxysmal Nocturnal Hemoglobinuria | Unknown | 2018-11-01 | 2025-03-29 | ClinicalTrials.gov |
| NCT03418389 | Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa … | — | Hypophosphatasia | Completed | 2018-09-05 | 2021-05-31 | ClinicalTrials.gov |
| NCT03418389 | Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa … | — | Hypophosphatasia | Completed | 2018-09-05 | 2021-05-31 | ClinicalTrials.gov |
| NCT05396742 | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombina… | Phase1 | Healthy | Completed | 2018-08-09 | 2019-05-21 | ClinicalTrials.gov |
| NCT05396742 | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombina… | Phase1 | Healthy | Completed | 2018-08-09 | 2019-05-21 | ClinicalTrials.gov |
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus… | Phase1 | Healthy | Completed | 2018-07-27 | 2018-10-17 | ClinicalTrials.gov |
| NCT05109390 | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus… | Phase1 | Healthy | Completed | 2018-07-27 | 2018-10-17 | ClinicalTrials.gov |
| NCT05016206 | A Study of the Cardiac Effects of Danicopan in Healthy Adults | Phase1 | Healthy | Completed | 2018-07-26 | 2018-10-12 | ClinicalTrials.gov |
| NCT05016206 | A Study of the Cardiac Effects of Danicopan in Healthy Adults | Phase1 | Healthy | Completed | 2018-07-26 | 2018-10-12 | ClinicalTrials.gov |
| NCT03346083 | Study Evaluating Betrixaban in Pediatric Participants | Phase1 | VTE Prophylaxis | Terminated | 2018-07-13 | 2019-10-08 | ClinicalTrials.gov |
| NCT03346083 | Study Evaluating Betrixaban in Pediatric Participants | Phase1 | VTE Prophylaxis | Terminated | 2018-07-13 | 2019-10-08 | ClinicalTrials.gov |
| NCT03459443 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MP… | Phase2 | C3 Glomerulonephritis | Terminated | 2018-06-20 | 2021-03-29 | ClinicalTrials.gov |
| NCT03459443 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MP… | Phase2 | C3 Glomerulonephritis | Terminated | 2018-06-20 | 2021-03-29 | ClinicalTrials.gov |
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants… | Phase2 | C3 Glomerulopathy | Completed | 2018-06-12 | 2020-12-18 | ClinicalTrials.gov |
| NCT03369236 | A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants… | Phase2 | C3 Glomerulopathy | Completed | 2018-06-12 | 2020-12-18 | ClinicalTrials.gov |
| NCT03472885 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria Wit… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2018-05-08 | 2023-01-05 | ClinicalTrials.gov |
| NCT03472885 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria Wit… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2018-05-08 | 2023-01-05 | ClinicalTrials.gov |
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2018-05-01 | 2018-09-21 | ClinicalTrials.gov |
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2018-05-01 | 2018-09-21 | ClinicalTrials.gov |
| NCT05884060 | Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-… | — | PNH | Completed | 2018-04-20 | 2022-03-01 | ClinicalTrials.gov |
| NCT05884060 | Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-… | — | PNH | Completed | 2018-04-20 | 2022-03-01 | ClinicalTrials.gov |
| NCT03574506 | Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associat… | — | Atypical Hemolytic Uremic Syndrome | Unknown | 2018-04-15 | 2020-11-30 | ClinicalTrials.gov |
| NCT03574506 | Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associat… | — | Atypical Hemolytic Uremic Syndrome | Unknown | 2018-04-15 | 2020-11-30 | ClinicalTrials.gov |
| NCT03580941 | Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies i… | — | Hemolytic-Uremic Syndrome | Unknown | 2018-04-15 | 2020-11-30 | ClinicalTrials.gov |
| NCT03580941 | Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies i… | — | Hemolytic-Uremic Syndrome | Unknown | 2018-04-15 | 2020-11-30 | ClinicalTrials.gov |
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal N… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2018-02-22 | 2022-08-25 | ClinicalTrials.gov |
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Ca… | Phase3 | Wilson Disease | Terminated | 2018-02-22 | 2023-06-30 | ClinicalTrials.gov |
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal N… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2018-02-22 | 2022-08-25 | ClinicalTrials.gov |
| NCT03403205 | Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Ca… | Phase3 | Wilson Disease | Terminated | 2018-02-22 | 2023-06-30 | ClinicalTrials.gov |
| NCT03766347 | Pediatric NMOSD Observational Study | — | Neuromyelitis Optica | Completed | 2018-02-01 | 2024-04-03 | ClinicalTrials.gov |
| NCT03766347 | Pediatric NMOSD Observational Study | — | Neuromyelitis Optica | Completed | 2018-02-01 | 2024-04-03 | ClinicalTrials.gov |
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants… | Phase1 | Healthy | Completed | 2018-01-24 | 2018-05-29 | ClinicalTrials.gov |
| NCT04935294 | Study of Danicopan in Participants With Normal Kidney Function and Participants… | Phase1 | Healthy | Completed | 2018-01-24 | 2018-05-29 | ClinicalTrials.gov |
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia… | Phase1 | Warm Autoimmune Hemolytic Anemia | Terminated | 2018-01-10 | 2019-08-06 | ClinicalTrials.gov |
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia… | Phase1 | Warm Autoimmune Hemolytic Anemia | Terminated | 2018-01-10 | 2019-08-06 | ClinicalTrials.gov |
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Particip… | Phase1 | Healthy | Completed | 2017-12-01 | 2018-03-21 | ClinicalTrials.gov |
| NCT03384186 | A Study of Modified Release Formulations of Danicopan in Healthy Adult Particip… | Phase1 | Healthy | Completed | 2017-12-01 | 2018-03-21 | ClinicalTrials.gov |
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | Phase1 | Healthy | Completed | 2017-11-28 | 2018-04-13 | ClinicalTrials.gov |
| NCT03423446 | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Se… | Phase1 | Hepatic Impairment | Completed | 2017-11-28 | 2018-06-15 | ClinicalTrials.gov |
| NCT05047458 | A Study of Single-dose ALXN2050 in Healthy Adults | Phase1 | Healthy | Completed | 2017-11-28 | 2018-04-13 | ClinicalTrials.gov |
| NCT03423446 | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Se… | Phase1 | Hepatic Impairment | Completed | 2017-11-28 | 2018-06-15 | ClinicalTrials.gov |
| NCT03302845 | A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Abs… | Phase1 | Drug-drug Interaction | Completed | 2017-09-21 | 2017-11-07 | ClinicalTrials.gov |
| NCT03302845 | A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Abs… | Phase1 | Drug-drug Interaction | Completed | 2017-09-21 | 2017-11-07 | ClinicalTrials.gov |
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | Phase1 | Healthy | Completed | 2017-09-14 | 2017-10-15 | ClinicalTrials.gov |
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | Phase1 | Healthy | Completed | 2017-09-14 | 2017-10-15 | ClinicalTrials.gov |
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic… | Phase3 | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2017-08-31 | 2022-12-20 | ClinicalTrials.gov |
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic… | Phase3 | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2017-08-31 | 2022-12-20 | ClinicalTrials.gov |
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in… | Phase2 | C3 Glomerulonephritis | Completed | 2017-08-09 | 2019-01-09 | ClinicalTrials.gov |
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in… | Phase2 | C3 Glomerulonephritis | Completed | 2017-08-09 | 2019-01-09 | ClinicalTrials.gov |
| NCT03075904 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris… | Phase1 | Pemphigus | Terminated | 2017-07-18 | 2019-01-16 | ClinicalTrials.gov |
| NCT03075904 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris… | Phase1 | Pemphigus | Terminated | 2017-07-18 | 2019-01-16 | ClinicalTrials.gov |
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Noct… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2017-06-22 | 2022-01-04 | ClinicalTrials.gov |
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Noct… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2017-06-22 | 2022-01-04 | ClinicalTrials.gov |
| NCT03056040 | ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemo… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2017-05-17 | 2022-02-21 | ClinicalTrials.gov |
| NCT03056040 | ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemo… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2017-05-17 | 2022-02-21 | ClinicalTrials.gov |
| NCT03108274 | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Myc… | Phase1 | Healthy | Completed | 2017-04-18 | 2017-06-16 | ClinicalTrials.gov |
| NCT03108274 | A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Myc… | Phase1 | Healthy | Completed | 2017-04-18 | 2017-06-16 | ClinicalTrials.gov |
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PN… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2017-03-31 | 2018-11-14 | ClinicalTrials.gov |
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PN… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2017-03-31 | 2018-11-14 | ClinicalTrials.gov |
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent … | Phase3 | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2017-01-11 | 2023-01-24 | ClinicalTrials.gov |
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent … | Phase3 | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2017-01-11 | 2023-01-24 | ClinicalTrials.gov |
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïv… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2016-12-12 | 2023-02-28 | ClinicalTrials.gov |
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïv… | Phase3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2016-12-12 | 2023-02-28 | ClinicalTrials.gov |
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | Phase1 | Advanced Solid Tumors | Terminated | 2016-11-17 | 2017-09-27 | ClinicalTrials.gov |
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | Phase1 | Advanced Solid Tumors | Terminated | 2016-11-17 | 2017-09-27 | ClinicalTrials.gov |
| NCT02926872 | Screening for Lysosomal Acid Lipase Deficiency | — | Lysosomal Acid Lipase Deficiency | Terminated | 2016-11-01 | 2017-06-05 | ClinicalTrials.gov |
| NCT02926872 | Screening for Lysosomal Acid Lipase Deficiency | — | Lysosomal Acid Lipase Deficiency | Terminated | 2016-11-01 | 2017-06-05 | ClinicalTrials.gov |
| NCT02796885 | Characterisation of Adult-Onset Hypophosphatasia | — | Hypophosphatasia | Completed | 2016-11-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT02796885 | Characterisation of Adult-Onset Hypophosphatasia | — | Hypophosphatasia | Completed | 2016-11-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT05288829 | A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2016-08-19 | 2017-07-18 | ClinicalTrials.gov |
| NCT05288829 | A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2016-08-19 | 2017-07-18 | ClinicalTrials.gov |
| NCT04940559 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled C… | Phase1 | Healthy | Completed | 2016-08-02 | 2016-10-05 | ClinicalTrials.gov |
| NCT04940559 | Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled C… | Phase1 | Healthy | Completed | 2016-08-02 | 2016-10-05 | ClinicalTrials.gov |
| NCT02797821 | Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With… | Phase2 | Hypophosphatasia | Completed | 2016-06-06 | 2017-06-21 | ClinicalTrials.gov |
| NCT02797821 | Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With… | Phase2 | Hypophosphatasia | Completed | 2016-06-06 | 2017-06-21 | ClinicalTrials.gov |
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | Phase1 | Healthy | Completed | 2016-05-21 | 2017-01-11 | ClinicalTrials.gov |
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | Phase1 | Healthy | Completed | 2016-05-21 | 2017-01-11 | ClinicalTrials.gov |
| NCT02763215 | The Assessment of Copper Parameters in Wilson Disease Participants on Standard … | — | Wilson Disease | Completed | 2016-05-19 | 2019-01-21 | ClinicalTrials.gov |
| NCT02763215 | The Assessment of Copper Parameters in Wilson Disease Participants on Standard … | — | Wilson Disease | Completed | 2016-05-19 | 2019-01-21 | ClinicalTrials.gov |
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Par… | Phase1 | Healthy | Completed | 2016-04-18 | 2017-07-05 | ClinicalTrials.gov |
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Par… | Phase1 | Healthy | Completed | 2016-04-18 | 2017-07-05 | ClinicalTrials.gov |
| NCT02226146 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Pa… | Phase2 | Pemphigoid, Bullous | Completed | 2016-02-29 | 2018-04-30 | ClinicalTrials.gov |
| NCT02226146 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Pa… | Phase2 | Pemphigoid, Bullous | Completed | 2016-02-29 | 2018-04-30 | ClinicalTrials.gov |
| NCT04889677 | Study of a Single Dose of Danicopan in Healthy Participants | Phase1 | Healthy | Completed | 2016-02-04 | 2016-06-21 | ClinicalTrials.gov |
| NCT04889677 | Study of a Single Dose of Danicopan in Healthy Participants | Phase1 | Healthy | Completed | 2016-02-04 | 2016-06-21 | ClinicalTrials.gov |
| NCT02605993 | Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Particip… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2016-01-04 | 2022-01-12 | ClinicalTrials.gov |
| NCT02605993 | Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Particip… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2016-01-04 | 2022-01-12 | ClinicalTrials.gov |
| NCT02647918 | Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Funct… | Phase1 | Renal Impairment | Completed | 2015-12-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02647918 | Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Funct… | Phase1 | Renal Impairment | Completed | 2015-12-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02598583 | Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal … | Phase1 | PNH | Completed | 2015-11-12 | 2021-03-11 | ClinicalTrials.gov |
| NCT02598583 | Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal … | Phase1 | PNH | Completed | 2015-11-12 | 2021-03-11 | ClinicalTrials.gov |
| NCT02614898 | Evaluation of Potential Predictors of Disease Progression in Participants With … | — | Atypical Hemolytic Uremic Syndrome | Terminated | 2015-11-04 | 2017-10-05 | ClinicalTrials.gov |
| NCT02614898 | Evaluation of Potential Predictors of Disease Progression in Participants With … | — | Atypical Hemolytic Uremic Syndrome | Terminated | 2015-11-04 | 2017-10-05 | ClinicalTrials.gov |
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subj… | Phase1 | Mucopolysaccharidosis III, Type B (MPS IIIB) | Terminated | 2015-10-15 | 2017-08-18 | ClinicalTrials.gov |
| NCT02618512 | A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subj… | Phase1 | Mucopolysaccharidosis III, Type B (MPS IIIB) | Terminated | 2015-10-15 | 2017-08-18 | ClinicalTrials.gov |
| NCT01671956 | Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilim… | Phase2 | Ulcerative Colitis, Active Moderate | Terminated | 2015-07-31 | 2018-11-14 | ClinicalTrials.gov |
| NCT01671956 | Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilim… | Phase2 | Ulcerative Colitis, Active Moderate | Terminated | 2015-07-31 | 2018-11-14 | ClinicalTrials.gov |
| NCT02512562 | A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokin… | Phase1 | Chronic Hepatitis C | Completed | 2015-07-31 | 2015-08-31 | ClinicalTrials.gov |
| NCT02512562 | A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokin… | Phase1 | Chronic Hepatitis C | Completed | 2015-07-31 | 2015-08-31 | ClinicalTrials.gov |
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2015-07-28 | 2016-09-01 | ClinicalTrials.gov |
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | Phase1 | Healthy | Completed | 2015-07-28 | 2016-09-01 | ClinicalTrials.gov |
| NCT02494609 | Oral Contraceptive DDI Study | Phase1 | Healthy | Unknown | 2015-07-01 | — | ClinicalTrials.gov |
| NCT02494609 | Oral Contraceptive DDI Study | Phase1 | Healthy | Unknown | 2015-07-01 | — | ClinicalTrials.gov |
| NCT02531867 | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypop… | Phase4 | Hypophosphatasia | Completed | 2015-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02471274 | PK Study of Sotagliflozin in Subjects With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2015-06-01 | — | ClinicalTrials.gov |
| NCT02471274 | PK Study of Sotagliflozin in Subjects With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2015-06-01 | — | ClinicalTrials.gov |
| NCT02531867 | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypop… | Phase4 | Hypophosphatasia | Completed | 2015-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of An… | Phase3 | Bleeding | Completed | 2015-04-10 | 2020-09-24 | ClinicalTrials.gov |
| NCT02329327 | A Study in Participants With Acute Major Bleeding to Evaluate the Ability of An… | Phase3 | Bleeding | Completed | 2015-04-10 | 2020-09-24 | ClinicalTrials.gov |
| NCT02373046 | Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets | Phase1 | Healthy | Completed | 2015-02-01 | — | ClinicalTrials.gov |
| NCT02113891 | Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transp… | Phase1 | Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Withdrawn | 2015-02-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02113891 | Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transp… | Phase1 | Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Withdrawn | 2015-02-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02373046 | Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets | Phase1 | Healthy | Completed | 2015-02-01 | — | ClinicalTrials.gov |
| NCT02324049 | Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolys… | Phase1 | Mucopolysaccharidosis IIIB | Completed | 2015-01-22 | 2017-10-16 | ClinicalTrials.gov |
| NCT02324049 | Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolys… | Phase1 | Mucopolysaccharidosis IIIB | Completed | 2015-01-22 | 2017-10-16 | ClinicalTrials.gov |
| NCT02306720 | Registry of Patients With Hypophosphatasia | — | Hypophosphatasia (HPP) | Enrolling_By_Invitation | 2015-01-20 | 2031-12-31 | ClinicalTrials.gov |
| NCT02306720 | Registry of Patients With Hypophosphatasia | — | Hypophosphatasia (HPP) | Enrolling_By_Invitation | 2015-01-20 | 2031-12-31 | ClinicalTrials.gov |
| NCT02003144 | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | Phase3 | Neuromyelitis Optica | Completed | 2015-01-12 | 2021-07-12 | ClinicalTrials.gov |
| NCT02003144 | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | Phase3 | Neuromyelitis Optica | Completed | 2015-01-12 | 2021-07-12 | ClinicalTrials.gov |
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | — | Cholesteryl Ester Storage Disease | Completed | 2015-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | — | Cholesteryl Ester Storage Disease | Completed | 2015-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02345421 | A Study to Identify and Characterize LAL-D Patients in High-risk Populations | — | Lysosomal Acid Lipase Deficiency | Terminated | 2014-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02345421 | A Study to Identify and Characterize LAL-D Patients in High-risk Populations | — | Lysosomal Acid Lipase Deficiency | Terminated | 2014-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02273596 | Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | Phase2 | Wilson Disease | Completed | 2014-11-24 | 2018-11-07 | ClinicalTrials.gov |
| NCT02273596 | Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | Phase2 | Wilson Disease | Completed | 2014-11-24 | 2018-11-07 | ClinicalTrials.gov |
| NCT02245412 | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower G… | Phase2 | Acute Graft-Versus-Host Disease | Terminated | 2014-11-14 | 2017-02-27 | ClinicalTrials.gov |
| NCT02245412 | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower G… | Phase2 | Acute Graft-Versus-Host Disease | Terminated | 2014-11-14 | 2017-02-27 | ClinicalTrials.gov |
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in … | Phase3 | Refractory Generalized Myasthenia Gravis | Completed | 2014-11-12 | 2019-01-15 | ClinicalTrials.gov |
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in … | Phase3 | Refractory Generalized Myasthenia Gravis | Completed | 2014-11-12 | 2019-01-15 | ClinicalTrials.gov |
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With A… | Phase1 | AL Amyloidosis | Completed | 2014-10-30 | 2017-07-13 | ClinicalTrials.gov |
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With A… | Phase1 | AL Amyloidosis | Completed | 2014-10-30 | 2017-07-13 | ClinicalTrials.gov |
| NCT02300350 | DDI Study With Multiple-dose LX4211 and Single Dose Digoxin | Phase1 | Healthy | Completed | 2014-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02300363 | DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin | Phase1 | Healthy | Completed | 2014-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02300363 | DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin | Phase1 | Healthy | Completed | 2014-10-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02300350 | DDI Study With Multiple-dose LX4211 and Single Dose Digoxin | Phase1 | Healthy | Completed | 2014-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Part… | — | MPS IIIB (Sanfilippo B Syndrome) | Terminated | 2014-09-14 | 2017-07-11 | ClinicalTrials.gov |
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Part… | — | MPS IIIB (Sanfilippo B Syndrome) | Terminated | 2014-09-14 | 2017-07-11 | ClinicalTrials.gov |
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | Phase1 | Healthy | Completed | 2014-08-27 | 2015-03-13 | ClinicalTrials.gov |
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | Phase1 | Healthy | Completed | 2014-08-27 | 2015-03-13 | ClinicalTrials.gov |
| NCT02145182 | Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | Phase2 | Delayed Graft Function | Completed | 2014-08-21 | 2016-11-22 | ClinicalTrials.gov |
| NCT02145182 | Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | Phase2 | Delayed Graft Function | Completed | 2014-08-21 | 2016-11-22 | ClinicalTrials.gov |
| NCT02235493 | Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patient… | — | Hypophosphatasia | Completed | 2014-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02235493 | Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patient… | — | Hypophosphatasia | Completed | 2014-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02157558 | An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenad… | Phase1 | Drug Interactions | Completed | 2014-07-01 | — | ClinicalTrials.gov |
| NCT02195635 | Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Inject… | Phase1 | Drug Interactions | Completed | 2014-07-01 | — | ClinicalTrials.gov |
| NCT02195635 | Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Inject… | Phase1 | Drug Interactions | Completed | 2014-07-01 | — | ClinicalTrials.gov |
| NCT02157558 | An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenad… | Phase1 | Drug Interactions | Completed | 2014-07-01 | — | ClinicalTrials.gov |
| NCT02112994 | Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Aci… | Phase2 | Lysosomal Acid Lipase Deficiency | Completed | 2014-06-24 | 2017-12-28 | ClinicalTrials.gov |
| NCT02112994 | Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Aci… | Phase2 | Lysosomal Acid Lipase Deficiency | Completed | 2014-06-24 | 2017-12-28 | ClinicalTrials.gov |
| NCT02193867 | Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Defici… | Phase2 | Lysosomal Acid Lipase Deficiency | Terminated | 2014-06-06 | 2018-10-30 | ClinicalTrials.gov |
| NCT02193867 | Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Defici… | Phase2 | Lysosomal Acid Lipase Deficiency | Terminated | 2014-06-06 | 2018-10-30 | ClinicalTrials.gov |
| NCT02157584 | An Open-Label Food Effect Study of Telotristat Etiprate | Phase1 | Healthy | Completed | 2014-06-01 | — | ClinicalTrials.gov |
| NCT02157584 | An Open-Label Food Effect Study of Telotristat Etiprate | Phase1 | Healthy | Completed | 2014-06-01 | — | ClinicalTrials.gov |
| NCT02155205 | A Thorough QT Study of Telotristat Etiprate | Phase1 | QT Interval | Completed | 2014-05-01 | — | ClinicalTrials.gov |
| NCT02147808 | A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam … | Phase1 | Drug Interactions | Completed | 2014-05-01 | — | ClinicalTrials.gov |
| NCT02155205 | A Thorough QT Study of Telotristat Etiprate | Phase1 | QT Interval | Completed | 2014-05-01 | — | ClinicalTrials.gov |
| NCT02147808 | A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam … | Phase1 | Drug Interactions | Completed | 2014-05-01 | — | ClinicalTrials.gov |
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participa… | Phase3 | Neuromyelitis Optica | Terminated | 2014-04-11 | 2018-07-17 | ClinicalTrials.gov |
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participa… | Phase3 | Neuromyelitis Optica | Terminated | 2014-04-11 | 2018-07-17 | ClinicalTrials.gov |
| NCT05319912 | A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omepr… | Phase1 | Healthy | Completed | 2014-04-07 | 2014-05-29 | ClinicalTrials.gov |
| NCT05319912 | A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omepr… | Phase1 | Healthy | Completed | 2014-04-07 | 2014-05-29 | ClinicalTrials.gov |
| NCT02128269 | Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of… | Phase2 | Antiphospholipid (aPL)-Positive | Terminated | 2014-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02128269 | Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of… | Phase2 | Antiphospholipid (aPL)-Positive | Terminated | 2014-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02063659 | Telotristat Etiprate for Carcinoid Syndrome Therapy | Phase3 | Carcinoid Syndrome | Completed | 2014-03-11 | 2016-03-29 | ClinicalTrials.gov |
| NCT02063659 | Telotristat Etiprate for Carcinoid Syndrome Therapy | Phase3 | Carcinoid Syndrome | Completed | 2014-03-11 | 2016-03-29 | ClinicalTrials.gov |
| NCT02104219 | Retrospective, Non-interventional Natural History of Patients With Juvenile-ons… | — | Hypophosphatasia (HPP) | Completed | 2014-03-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02104219 | Retrospective, Non-interventional Natural History of Patients With Juvenile-ons… | — | Hypophosphatasia (HPP) | Completed | 2014-03-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In He… | Phase1 | Healthy | Completed | 2014-01-20 | 2014-03-24 | ClinicalTrials.gov |
| NCT05319899 | A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In He… | Phase1 | Healthy | Completed | 2014-01-20 | 2014-03-24 | ClinicalTrials.gov |
| NCT02026063 | Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome … | Phase3 | Carcinoid Syndrome | Completed | 2014-01-14 | 2018-09-12 | ClinicalTrials.gov |
| NCT02026063 | Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome … | Phase3 | Carcinoid Syndrome | Completed | 2014-01-14 | 2018-09-12 | ClinicalTrials.gov |
| NCT02090179 | Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS… | — | MPS IIIB (Sanfilippo B Syndrome) | Completed | 2013-12-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (… | Phase3 | Refractory Generalized Myasthenia Gravis | Completed | 2013-12-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (… | Phase3 | Refractory Generalized Myasthenia Gravis | Completed | 2013-12-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02090179 | Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS… | — | MPS IIIB (Sanfilippo B Syndrome) | Completed | 2013-12-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01895127 | Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection … | Phase2 | Antibody-mediated Rejection | Terminated | 2013-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01895127 | Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection … | Phase2 | Antibody-mediated Rejection | Terminated | 2013-11-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | Phase1 | Follicular Lymphoma (FL/Indolent NHL) | Completed | 2013-08-30 | 2020-12-15 | ClinicalTrials.gov |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | Phase1 | Follicular Lymphoma (FL/Indolent NHL) | Completed | 2013-08-30 | 2020-12-15 | ClinicalTrials.gov |
| NCT01919346 | Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplanta… | Phase2 | Delayed Graft Function | Terminated | 2013-08-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01932528 | An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [1… | Phase1 | Carcinoid Syndrome | Completed | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01916850 | Study to Determine the Safety, Tolerability and Pharmacokinetics Following Mult… | Phase1 | Healthy | Completed | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01916863 | Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Int… | Phase1 | Healthy Subjects | Completed | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01932528 | An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [1… | Phase1 | Carcinoid Syndrome | Completed | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01916863 | Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Int… | Phase1 | Healthy Subjects | Completed | 2013-08-01 | — | ClinicalTrials.gov |
| NCT01919346 | Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplanta… | Phase2 | Delayed Graft Function | Terminated | 2013-08-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01916850 | Study to Determine the Safety, Tolerability and Pharmacokinetics Following Mult… | Phase1 | Healthy | Completed | 2013-08-01 | — | ClinicalTrials.gov |
| NCT02293382 | A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Ty… | — | MPS IIIB (Sanfilippo Syndrome) | Completed | 2013-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02293382 | A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Ty… | — | MPS IIIB (Sanfilippo Syndrome) | Completed | 2013-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01913002 | Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Hea… | Phase1 | Healthy | Completed | 2013-07-01 | — | ClinicalTrials.gov |
| NCT01913002 | Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Hea… | Phase1 | Healthy | Completed | 2013-07-01 | — | ClinicalTrials.gov |
| NCT01883544 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Subjects | Completed | 2013-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01883544 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Subjects | Completed | 2013-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01633489 | Lysosomal Acid Lipase (LAL) Deficiency Registry | — | Lysosomal Acid Lipase Deficiency | Recruiting | 2013-05-30 | 2029-08-30 | ClinicalTrials.gov |
| NCT01633489 | Lysosomal Acid Lipase (LAL) Deficiency Registry | — | Lysosomal Acid Lipase Deficiency | Recruiting | 2013-05-30 | 2029-08-30 | ClinicalTrials.gov |
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Rib… | Phase2 | Hepatitis C, Chronic | Completed | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Rib… | Phase2 | Hepatitis C, Chronic | Completed | 2013-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | — | Atypical Hemolytic-Uremic Syndrome | Recruiting | 2013-03-18 | 2031-01-01 | ClinicalTrials.gov |
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | — | Atypical Hemolytic-Uremic Syndrome | Recruiting | 2013-03-18 | 2031-01-01 | ClinicalTrials.gov |
| NCT01818232 | Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in … | Phase1 | Healthy | Completed | 2013-03-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01818232 | Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in … | Phase1 | Healthy | Completed | 2013-03-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01757184 | Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participan… | Phase3 | Lysosomal Acid Lipase Deficiency | Completed | 2013-01-22 | 2018-12-11 | ClinicalTrials.gov |
| NCT01757184 | Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participan… | Phase3 | Lysosomal Acid Lipase Deficiency | Completed | 2013-01-22 | 2018-12-11 | ClinicalTrials.gov |
| NCT01677910 | TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Control… | Phase3 | Carcinoid Syndrome | Completed | 2013-01-08 | 2016-03-21 | ClinicalTrials.gov |
| NCT01677910 | TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Control… | Phase3 | Carcinoid Syndrome | Completed | 2013-01-08 | 2016-03-21 | ClinicalTrials.gov |
| NCT02013037 | The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Trans… | Phase3 | Antibody-mediated Rejection | Completed | 2012-11-01 | 2020-04-30 | ClinicalTrials.gov |
| NCT02013037 | The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Trans… | Phase3 | Antibody-mediated Rejection | Completed | 2012-11-01 | 2020-04-30 | ClinicalTrials.gov |
| NCT01700179 | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus … | Phase1 | Chronic Hepatitis C Infection | Completed | 2012-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01700179 | Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus … | Phase1 | Chronic Hepatitis C Infection | Completed | 2012-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01567085 | Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipien… | Phase2 | Stage V Chronic Kidney Disease | Completed | 2012-08-29 | 2017-05-24 | ClinicalTrials.gov |
| NCT01567085 | Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipien… | Phase2 | Stage V Chronic Kidney Disease | Completed | 2012-08-29 | 2017-05-24 | ClinicalTrials.gov |
| NCT01419028 | A Retrospective Study of the Natural History of Patients With Severe Perinatal … | — | Hypophosphatasia (HPP) | Completed | 2012-08-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01716728 | Identification of Undiagnosed Lysosomal Acid Lipase Deficiency | Na | Lysosomal Acid Lipase Deficiency | Unknown | 2012-08-01 | — | ClinicalTrials.gov |
| NCT01419028 | A Retrospective Study of the Natural History of Patients With Severe Perinatal … | — | Hypophosphatasia (HPP) | Completed | 2012-08-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01716728 | Identification of Undiagnosed Lysosomal Acid Lipase Deficiency | Na | Lysosomal Acid Lipase Deficiency | Unknown | 2012-08-01 | — | ClinicalTrials.gov |
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemoly… | Phase2 | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2012-05-16 | 2013-09-25 | ClinicalTrials.gov |
| NCT01757431 | The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemoly… | Phase2 | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2012-05-16 | 2013-09-25 | ClinicalTrials.gov |
| NCT01755429 | To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS … | — | ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01755429 | To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS … | — | ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | Completed | 2012-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01528111 | Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects … | Phase1 | Primary Open-angle Glaucoma | Completed | 2012-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01555008 | Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in … | Phase1 | Type 2 Diabetes Mellitus | Completed | 2012-03-01 | — | ClinicalTrials.gov |
| NCT01412047 | Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study | — | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2012-03-01 | 2013-06-30 | ClinicalTrials.gov |
| NCT01522170 | aHUS Observational Long Term Follow-Up | — | Atypical Hemolytic Uremic Syndrome | Terminated | 2012-03-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01522170 | aHUS Observational Long Term Follow-Up | — | Atypical Hemolytic Uremic Syndrome | Terminated | 2012-03-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01412047 | Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study | — | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2012-03-01 | 2013-06-30 | ClinicalTrials.gov |
| NCT01528111 | Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects … | Phase1 | Primary Open-angle Glaucoma | Completed | 2012-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01555008 | Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in … | Phase1 | Type 2 Diabetes Mellitus | Completed | 2012-03-01 | — | ClinicalTrials.gov |
| NCT01494233 | A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects… | Phase2 | Irritable Bowel Syndrome | Completed | 2012-02-01 | — | ClinicalTrials.gov |
| NCT01494233 | A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects… | Phase2 | Irritable Bowel Syndrome | Completed | 2012-02-01 | — | ClinicalTrials.gov |
| NCT01456052 | A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Par… | Phase2 | Ulcerative Colitis | Completed | 2012-01-30 | 2013-09-03 | ClinicalTrials.gov |
| NCT01456052 | A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Par… | Phase2 | Ulcerative Colitis | Completed | 2012-01-30 | 2013-09-03 | ClinicalTrials.gov |
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of… | Phase2 | Cholesterol Ester Storage Disease (CESD) | Completed | 2011-12-12 | 2017-06-21 | ClinicalTrials.gov |
| NCT01488097 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of… | Phase2 | Cholesterol Ester Storage Disease (CESD) | Completed | 2011-12-12 | 2017-06-21 | ClinicalTrials.gov |
| NCT01403389 | A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function … | Phase2 | Delayed Function of Renal Transplant | Terminated | 2011-12-01 | 2014-02-06 | ClinicalTrials.gov |
| NCT01403389 | A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function … | Phase2 | Delayed Function of Renal Transplant | Terminated | 2011-12-01 | 2014-02-06 | ClinicalTrials.gov |
| NCT01399593 | Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplan… | Phase2 | Antibody Mediated Rejection | Terminated | 2011-11-02 | 2015-11-13 | ClinicalTrials.gov |
| NCT01399593 | Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplan… | Phase2 | Antibody Mediated Rejection | Terminated | 2011-11-02 | 2015-11-13 | ClinicalTrials.gov |
| NCT01454986 | Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjec… | Phase1 | Healthy | Completed | 2011-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01454986 | Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjec… | Phase1 | Healthy | Completed | 2011-11-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT01441232 | A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administratio… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2011-10-01 | — | ClinicalTrials.gov |
| NCT01441232 | A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administratio… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2011-10-01 | — | ClinicalTrials.gov |
| NCT01417052 | A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active … | Phase1 | Rheumatoid Arthritis | Completed | 2011-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01417052 | A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active … | Phase1 | Rheumatoid Arthritis | Completed | 2011-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01411800 | An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects | Phase1 | Irritable Bowel Syndrome | Completed | 2011-08-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01411800 | An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects | Phase1 | Irritable Bowel Syndrome | Completed | 2011-08-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Co… | Phase2 | Shiga-like Toxin-producing Escherichia Coli | Completed | 2011-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Co… | Phase2 | Shiga-like Toxin-producing Escherichia Coli | Completed | 2011-07-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01376557 | Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With I… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2011-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01376557 | Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With I… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2011-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01528917 | An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Choles… | — | Cholesterol Ester Storage Disease(CESD) | Completed | 2011-06-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01528917 | An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Choles… | — | Cholesterol Ester Storage Disease(CESD) | Completed | 2011-06-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01371825 | Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebel… | Phase2 | Lysosomal Acid Lipase Deficiency | Completed | 2011-05-04 | 2018-01-03 | ClinicalTrials.gov |
| NCT01371825 | Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebel… | Phase2 | Lysosomal Acid Lipase Deficiency | Completed | 2011-05-04 | 2018-01-03 | ClinicalTrials.gov |
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (A… | Phase2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Withdrawn | 2011-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (A… | Phase2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Withdrawn | 2011-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01307098 | Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult… | Phase1 | Cholesterol Ester Storage Disease(CESD) | Completed | 2011-04-25 | 2012-01-06 | ClinicalTrials.gov |
| NCT01307098 | Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult… | Phase1 | Cholesterol Ester Storage Disease(CESD) | Completed | 2011-04-25 | 2012-01-06 | ClinicalTrials.gov |
| NCT01335165 | Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemog… | Phase1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Terminated | 2011-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01335165 | Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemog… | Phase1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Terminated | 2011-04-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01334242 | A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Health… | Phase1 | Healthy | Completed | 2011-03-01 | — | ClinicalTrials.gov |
| NCT01334242 | A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Health… | Phase1 | Healthy | Completed | 2011-03-01 | — | ClinicalTrials.gov |
| NCT01327573 | Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplanta… | Phase1 | Kidney; Complications, Allograft | Completed | 2011-03-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01327573 | Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplanta… | Phase1 | Kidney; Complications, Allograft | Completed | 2011-03-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01292993 | A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects | Phase1 | Type 2 Diabetes Mellitus | Completed | 2011-02-01 | — | ClinicalTrials.gov |
| NCT01292993 | A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects | Phase1 | Type 2 Diabetes Mellitus | Completed | 2011-02-01 | — | ClinicalTrials.gov |
| NCT01303952 | Therapy of Chronic Cold Agglutinin Disease With Eculizumab | Phase2 | Cold Agglutinin Disease | Completed | 2011-01-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01303952 | Therapy of Chronic Cold Agglutinin Disease With Eculizumab | Phase2 | Cold Agglutinin Disease | Completed | 2011-01-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01358370 | A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase De… | — | Lysosomal Acid Lipase Deficiency | Completed | 2010-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01358370 | A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase De… | — | Lysosomal Acid Lipase Deficiency | Completed | 2010-11-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01193348 | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients … | Phase2 | Atypical Hemolytic-Uremic Syndrome | Completed | 2010-09-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01188863 | Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Melli… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2010-09-01 | — | ClinicalTrials.gov |
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combi… | Phase2 | Hepatitis C | Completed | 2010-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01193348 | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients … | Phase2 | Atypical Hemolytic-Uremic Syndrome | Completed | 2010-09-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01192425 | Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood… | — | Hemoglobinuria | Completed | 2010-09-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01188863 | Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Melli… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2010-09-01 | — | ClinicalTrials.gov |
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combi… | Phase2 | Hepatitis C | Completed | 2010-09-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01192425 | Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood… | — | Hemoglobinuria | Completed | 2010-09-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Phase1 | Dense Deposit Disease | Completed | 2010-07-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01176266 | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With… | Phase2 | Hypophosphatasia | Completed | 2010-07-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01176266 | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With… | Phase2 | Hypophosphatasia | Completed | 2010-07-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01194973 | An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With… | Phase2 | Atypical Hemolytic-Uremic Syndrome | Completed | 2010-07-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01194973 | An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With… | Phase2 | Atypical Hemolytic-Uremic Syndrome | Completed | 2010-07-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Phase1 | Dense Deposit Disease | Completed | 2010-07-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01104415 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcino… | Phase2 | Carcinoid Syndrome | Completed | 2010-06-15 | 2014-02-12 | ClinicalTrials.gov |
| NCT01104415 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcino… | Phase2 | Carcinoid Syndrome | Completed | 2010-06-15 | 2014-02-12 | ClinicalTrials.gov |
| NCT01163149 | Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypop… | Phase2 | Hypophosphatasia | Completed | 2010-06-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01163149 | Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypop… | Phase2 | Hypophosphatasia | Completed | 2010-06-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01095887 | Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatib… | Phase1 | Kidney Transplant | Terminated | 2010-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01095887 | Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatib… | Phase1 | Kidney Transplant | Terminated | 2010-05-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01203826 | Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children Wit… | Phase2 | Hypophosphatasia (HPP) | Completed | 2010-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01203826 | Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children Wit… | Phase2 | Hypophosphatasia (HPP) | Completed | 2010-04-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01106027 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossm… | Phase1 | Kidney Transplant | Terminated | 2010-03-01 | 2016-08-19 | ClinicalTrials.gov |
| NCT01106027 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossm… | Phase1 | Kidney Transplant | Terminated | 2010-03-01 | 2016-08-19 | ClinicalTrials.gov |
| NCT00867932 | Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paro… | Phase4 | Hemoglobinuria, Paroxysmal | Completed | 2009-10-02 | 2011-05-12 | ClinicalTrials.gov |
| NCT00867932 | Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paro… | Phase4 | Hemoglobinuria, Paroxysmal | Completed | 2009-10-02 | 2011-05-12 | ClinicalTrials.gov |
| NCT00952484 | Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia… | Phase2 | Hypophosphatasia (HPP) | Completed | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00952484 | Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia… | Phase2 | Hypophosphatasia (HPP) | Completed | 2009-09-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT01770951 | A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab T… | — | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2009-08-31 | 2010-11-30 | ClinicalTrials.gov |
| NCT01770951 | A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab T… | — | Atypical Hemolytic Uremic Syndrome (aHUS) | Completed | 2009-08-31 | 2010-11-30 | ClinicalTrials.gov |
| NCT00962065 | Study of LX4211 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Type 2 Diabetes Mellitus | Completed | 2009-08-01 | — | ClinicalTrials.gov |
| NCT00962065 | Study of LX4211 in Subjects With Type 2 Diabetes Mellitus | Phase2 | Type 2 Diabetes Mellitus | Completed | 2009-08-01 | — | ClinicalTrials.gov |
| NCT00844428 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Th… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00903383 | Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotre… | Phase2 | Rheumatoid Arthritis | Completed | 2009-07-01 | — | ClinicalTrials.gov |
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00844428 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Th… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasi… | Phase2 | Hypophosphatasia | Withdrawn | 2009-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macula… | Phase2 | Age-Related Macular Degeneration | Completed | 2009-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasi… | Phase2 | Hypophosphatasia | Withdrawn | 2009-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macula… | Phase2 | Age-Related Macular Degeneration | Completed | 2009-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT00903383 | Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotre… | Phase2 | Rheumatoid Arthritis | Completed | 2009-07-01 | — | ClinicalTrials.gov |
| NCT00838513 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00844545 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00844844 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Th… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00844844 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Th… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT00844545 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy… | Phase2 | Atypical Hemolytic Uremic Syndrome | Completed | 2009-05-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01205152 | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and … | Phase2 | Hypophosphatasia | Completed | 2009-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00904826 | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | Phase1 | Neuromyelitis Optica | Completed | 2009-04-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00904826 | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | Phase1 | Neuromyelitis Optica | Completed | 2009-04-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01205152 | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and … | Phase2 | Hypophosphatasia | Completed | 2009-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00853047 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcino… | Phase2 | Carcinoid Syndrome | Completed | 2009-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00853047 | Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcino… | Phase2 | Carcinoid Syndrome | Completed | 2009-03-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00847886 | Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis | Phase1 | Rheumatoid Arthritis | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00847886 | Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis | Phase1 | Rheumatoid Arthritis | Completed | 2009-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00813098 | Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome | Phase2 | Irritable Bowel Syndrome | Completed | 2008-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00813098 | Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome | Phase2 | Irritable Bowel Syndrome | Completed | 2008-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized… | Phase2 | Myasthenia Gravis | Terminated | 2008-10-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized… | Phase2 | Myasthenia Gravis | Terminated | 2008-10-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00744042 | Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hy… | Phase1 | Hypophosphatasia (HPP) | Completed | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00744042 | Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hy… | Phase1 | Hypophosphatasia (HPP) | Completed | 2008-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00739505 | Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusi… | Phase1 | Hypophosphatasia (HPP) | Completed | 2008-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00739505 | Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusi… | Phase1 | Hypophosphatasia (HPP) | Completed | 2008-08-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory C… | Phase1 | B-cell Chronic Lymphocytic Leukemia | Terminated | 2008-06-19 | 2010-12-14 | ClinicalTrials.gov |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory C… | Phase1 | B-cell Chronic Lymphocytic Leukemia | Terminated | 2008-06-19 | 2010-12-14 | ClinicalTrials.gov |
| NCT00675844 | An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment | Phase2 | HIV Infections | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00675844 | An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment | Phase2 | HIV Infections | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Noctur… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2008-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Noctur… | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2008-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00670774 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross … | Phase1 | Kidney Transplant | Completed | 2008-03-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT00670774 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross … | Phase1 | Kidney Transplant | Completed | 2008-03-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT00691808 | Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment | Phase2 | Age-Related Memory Disorders | Completed | 2008-02-01 | — | ClinicalTrials.gov |
| NCT00691808 | Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment | Phase2 | Age-Related Memory Disorders | Completed | 2008-02-01 | — | ClinicalTrials.gov |
| NCT01192399 | Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria … | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2007-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00546260 | Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary P… | Phase2 | Myocardial Infarction | Terminated | 2007-11-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00546260 | Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary P… | Phase2 | Myocardial Infarction | Terminated | 2007-11-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT01192399 | Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria … | Phase2 | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2007-11-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00485576 | Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma | Phase2 | Allergic Asthma | Completed | 2007-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00485576 | Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma | Phase2 | Allergic Asthma | Completed | 2007-09-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00401947 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antivira… | Phase2 | HCV Infection | Terminated | 2006-11-30 | 2007-03-31 | ClinicalTrials.gov |
| NCT00401947 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antivira… | Phase2 | HCV Infection | Terminated | 2006-11-30 | 2007-03-31 | ClinicalTrials.gov |
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Backgro… | Phase2 | Human Immunodeficiency Virus (HIV)-1 Infection | Completed | 2006-09-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Backgro… | Phase2 | Human Immunodeficiency Virus (HIV)-1 Infection | Completed | 2006-09-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00350272 | Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human… | Phase2 | HIV Infections | Completed | 2006-05-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00350272 | Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human… | Phase2 | HIV Infections | Completed | 2006-05-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00312039 | Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Docum… | Phase1 | HIV Infections | Completed | 2006-03-31 | 2007-10-31 | ClinicalTrials.gov |
| NCT00312039 | Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Docum… | Phase1 | HIV Infections | Completed | 2006-03-31 | 2007-10-31 | ClinicalTrials.gov |
| NCT00122317 | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal… | Phase3 | Paroxysmal Hemoglobinuria, Nocturnal | Completed | 2005-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00122317 | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal… | Phase3 | Paroxysmal Hemoglobinuria, Nocturnal | Completed | 2005-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients… | Phase3 | Hemoglobinuria, Paroxysmal | Completed | 2004-12-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00122304 | Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients… | Phase3 | Hemoglobinuria, Paroxysmal | Completed | 2004-12-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT01374360 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | — | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2004-10-29 | 2025-04-14 | ClinicalTrials.gov |
| NCT01374360 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | — | Paroxysmal Nocturnal Hemoglobinuria | Completed | 2004-10-29 | 2025-04-14 | ClinicalTrials.gov |
| NCT00122330 | Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobin… | Phase3 | Hemoglobinuria, Paroxysmal | Completed | 2004-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00122330 | Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobin… | Phase3 | Hemoglobinuria, Paroxysmal | Completed | 2004-10-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00088179 | Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiop… | Phase3 | Coronary Artery Disease | Completed | 2004-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00088179 | Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiop… | Phase3 | Coronary Artery Disease | Completed | 2004-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00040144 | Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-… | Phase2 | Chronic Hepatitis B | Terminated | 2002-07-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00040144 | Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-… | Phase2 | Chronic Hepatitis B | Terminated | 2002-07-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-n… | Phase2 | Hepatitis B, Chronic | Completed | 2002-02-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-n… | Phase2 | Hepatitis B, Chronic | Completed | 2002-02-01 | 2003-01-01 | ClinicalTrials.gov |
| NCT00048308 | Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patie… | Phase3 | Cardio-pulmonary Bypass | Completed | 2002-01-01 | — | ClinicalTrials.gov |
| NCT00048308 | Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patie… | Phase3 | Cardio-pulmonary Bypass | Completed | 2002-01-01 | — | ClinicalTrials.gov |
Total clinical trials: 670
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AZD0120 | Other | Phase PHASE1 | Relapsed AL Amyloidosis | RECRUITING | NCT07081646 |
| cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| Placebo | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| CAEL-101 | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| Ravulizumab | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT05746559 |
| Placebo | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT05746559 |
| PRT060128 Potassium | Other | Phase PHASE2 | Myocardial Infarction | TERMINATED | NCT00546260 |
| placebo | Other | Phase PHASE2 | Myocardial Infarction | TERMINATED | NCT00546260 |
| Ravulizumab | Other | Phase PHASE2 | Neuromyelitis Optica Spectrum Disorder | ACTIVE_NOT_RECRUITING | NCT05346354 |
| Placebo | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079281 |
| ALXN1850 | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079281 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT06291376 |
| Ravulizumab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | ACTIVE_NOT_RECRUITING | NCT06291376 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Danicopan | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05389449 |
| Ravulizumab | Other | Phase PHASE3 | NMOSD | NOT_YET_RECRUITING | NCT07557420 |
| Placebo | Other | Phase PHASE2 | Antibody-Mediated Rejection | RECRUITING | NCT06744647 |
| ALXN2030 | Other | Phase PHASE2 | Antibody-Mediated Rejection | RECRUITING | NCT06744647 |
| Ravulizumab | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT05746559 |
| Placebo | Other | Phase PHASE3 | Chronic Kidney Disease | COMPLETED | NCT05746559 |
| Best supportive care | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04543591 |
| Placebo | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04543591 |
| Ravulizumab | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04543591 |
| Placebo | Other | Phase PHASE3 | Delayed Graft Function | RECRUITING | NCT06830798 |
| Ravulizumab | Other | Phase PHASE3 | Delayed Graft Function | RECRUITING | NCT06830798 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05556096 |
| ALXN1720 | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05556096 |
| cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| Placebo | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| CAEL-101 | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| Tarperprumig | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| Placebo | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| Volagidemab | Other | Phase PHASE1 | Type 1 Diabetes | ACTIVE_NOT_RECRUITING | NCT05696366 |
| Sotagliflozin | Other | Phase PHASE1 | Type 1 Diabetes | ACTIVE_NOT_RECRUITING | NCT05696366 |
| ALXN2350 | Other | Phase PHASE1 | BAG3 Mutation Associated Dilated Cardiomyopathy | RECRUITING | NCT07218887 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT06578949 |
| Ravulizumab | Other | Phase PHASE3 | NMOSD | NOT_YET_RECRUITING | NCT07557420 |
| Tarperprumig | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| Placebo | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| Danicopan | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | AVAILABLE | NCT05982938 |
| Placebo | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079281 |
| ALXN1850 | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079281 |
| Placebo | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079359 |
| ALXN1850 | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079359 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07596784 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| eculizumab | Other | Phase PHASE3 | Hemoglobinuria, Paroxysmal | COMPLETED | NCT00122330 |
| eculizumab | Other | Phase PHASE3 | Hemoglobinuria, Paroxysmal | COMPLETED | NCT00122330 |
| eculizumab | Other | Phase PHASE3 | Hemoglobinuria, Paroxysmal | COMPLETED | NCT00122304 |
| eculizumab | Other | Phase PHASE3 | Hemoglobinuria, Paroxysmal | COMPLETED | NCT00122304 |
| eculizumab | Other | Phase PHASE2 | Allergic Asthma | COMPLETED | NCT00485576 |
| eculizumab | Other | Phase PHASE2 | Allergic Asthma | COMPLETED | NCT00485576 |
| ACH-126, 443 (beta-L-Fd4C) | Other | Approved | Chronic Hepatitis B | TERMINATED | NCT00037622 |
| ACH-126, 443 (beta-L-Fd4C) | Other | Approved | Chronic Hepatitis B | TERMINATED | NCT00037622 |
| ACH-126, 443 (beta-L-Fd4C) | Other | Approved | Chronic Hepatitis B | TERMINATED | NCT00037622 |
| Eculizumab (Soliris®) | Other | Phase PHASE2 | Shiga-like Toxin-producing Escherichia Coli | COMPLETED | NCT01410916 |
| enzyme analysis | Other | Approved | Lysosomal Acid Lipase Deficiency | UNKNOWN | NCT01716728 |
| Eculizumab | Other | Phase PHASE1 | Neuromyelitis Optica | COMPLETED | NCT00904826 |
| Eculizumab | Other | Phase PHASE1 | Neuromyelitis Optica | COMPLETED | NCT00904826 |
| ALXN1007 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01883544 |
| eculizumab | Other | Preclinical | Hemoglobinuria, Paroxysmal | APPROVED_FOR_MARKETING | NCT00438789 |
| ALXN1103 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT01335165 |
| ALXN1102 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT01335165 |
| ALXN1103 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT01335165 |
| ALXN1102 | Other | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT01335165 |
| Eculizumab | Other | Phase PHASE1 | Kidney Transplant | TERMINATED | NCT01095887 |
| Eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | COMPLETED | NCT00844844 |
| Eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | COMPLETED | NCT00844545 |
| Eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | COMPLETED | NCT00844545 |
| eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | COMPLETED | NCT00844428 |
| eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | COMPLETED | NCT00838513 |
| eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | COMPLETED | NCT00838513 |
| ACH126-443 (Beta-L-Fd4C) | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00040157 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01454986 |
| ALXN1007 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01454986 |
| eculizumab | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | WITHDRAWN | NCT01275287 |
| Standard of care treatment | Drug | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | WITHDRAWN | NCT01275287 |
| Eculizumab | Other | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome (aHUS) | COMPLETED | NCT01757431 |
| Asfotase Alfa | Other | Phase PHASE4 | Hypophosphatasia | COMPLETED | NCT02531867 |
| Asfotase Alfa | Other | Phase PHASE4 | Hypophosphatasia | COMPLETED | NCT02531867 |
| Eculizumab | Other | Phase PHASE2 | Atypical Hemolytic-Uremic Syndrome | COMPLETED | NCT01194973 |
| Saline | Other | Phase PHASE2 | Age-Related Macular Degeneration | COMPLETED | NCT00935883 |
| Eculizumab | Other | Phase PHASE2 | Age-Related Macular Degeneration | COMPLETED | NCT00935883 |
| There is no intervention in the study | Other | Preclinical | Lysosomal Acid Lipase Deficiency | TERMINATED | NCT02926872 |
| Plasmapheresis | Other | Phase PHASE2 | Antibody-mediated Rejection | TERMINATED | NCT01895127 |
| Immunoglobulin | Other | Phase PHASE2 | Antibody-mediated Rejection | TERMINATED | NCT01895127 |
| Eculizumab | Other | Phase PHASE2 | Antibody-mediated Rejection | TERMINATED | NCT01895127 |
| Eculizumab | Other | Phase PHASE2 | Antibody Mediated Rejection | TERMINATED | NCT01399593 |
| Eculizumab | Other | Phase PHASE1 | Kidney Transplant | TERMINATED | NCT01106027 |
| pexelizumab in conjunction with CABG | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00088179 |
| Normal Saline | Other | Phase PHASE2 | Delayed Graft Function | TERMINATED | NCT01919346 |
| Eculizumab | Other | Phase PHASE2 | Delayed Graft Function | TERMINATED | NCT01919346 |
| eculizumab | Other | Phase PHASE3 | Paroxysmal Hemoglobinuria, Nocturnal | COMPLETED | NCT00122317 |
| SBC-103 | Other | Phase PHASE1 | Mucopolysaccharidosis III, Type B (MPS IIIB) | TERMINATED | NCT02618512 |
| SBC-103 | Other | Phase PHASE1 | Mucopolysaccharidosis III, Type B (MPS IIIB) | TERMINATED | NCT02618512 |
| SBC-103 | Other | Phase PHASE1 | Mucopolysaccharidosis IIIB | COMPLETED | NCT02324049 |
| Eculizumab | Other | Phase PHASE4 | Hemoglobinuria, Paroxysmal | COMPLETED | NCT00867932 |
| Sebelipase alfa 3 mg/kg | Other | Phase PHASE1 | Cholesterol Ester Storage Disease(CESD) | COMPLETED | NCT01307098 |
| Sebelipase alfa 1 mg/kg | Other | Phase PHASE1 | Cholesterol Ester Storage Disease(CESD) | COMPLETED | NCT01307098 |
| Sebelipase alfa 0.35 mg/kg | Other | Phase PHASE1 | Cholesterol Ester Storage Disease(CESD) | COMPLETED | NCT01307098 |
| Placebo | Other | Phase PHASE2 | Delayed Graft Function | COMPLETED | NCT02145182 |
| Eculizumab | Other | Phase PHASE2 | Delayed Graft Function | COMPLETED | NCT02145182 |
| ALXN1007 20 mg/kg twice weekly | Other | Phase PHASE2 | Acute Graft-Versus-Host Disease | TERMINATED | NCT02245412 |
| ALXN1007 20 mg/kg once weekly | Other | Phase PHASE2 | Acute Graft-Versus-Host Disease | TERMINATED | NCT02245412 |
| ALXN1007 10 mg/kg once weekly | Other | Phase PHASE2 | Acute Graft-Versus-Host Disease | TERMINATED | NCT02245412 |
| Eculizumab | Other | Phase PHASE1 | Dense Deposit Disease | COMPLETED | NCT01221181 |
| Samalizumab | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | TERMINATED | NCT00648739 |
| Samalizumab | Other | Phase PHASE1 | B-cell Chronic Lymphocytic Leukemia | TERMINATED | NCT00648739 |
| Retrospective Case Only | Other | Preclinical | Hypophosphatasia | COMPLETED | NCT02235493 |
| asfotase alfa | Other | Phase PHASE2 | Hypophosphatasia | COMPLETED | NCT01205152 |
| Asfotase Alfa | Other | Phase PHASE2 | Hypophosphatasia (HPP) | COMPLETED | NCT01203826 |
| asfotase alfa | Other | Phase PHASE2 | Hypophosphatasia | COMPLETED | NCT01163149 |
| asfotase alfa | Other | Preclinical | Hypophosphatasia | APPROVED_FOR_MARKETING | NCT02496689 |
| asfotase alfa | Other | Preclinical | Hypophosphatasia | APPROVED_FOR_MARKETING | NCT02496689 |
| Asfotase Alfa | Other | Phase PHASE1 | Hypophosphatasia (HPP) | COMPLETED | NCT00739505 |
| asfotase alfa | Other | Phase PHASE2 | Hypophosphatasia (HPP) | COMPLETED | NCT00952484 |
| asfotase alfa | Other | Phase PHASE1 | Hypophosphatasia (HPP) | COMPLETED | NCT00744042 |
| Eculizumab | Other | Phase PHASE2 | Stage V Chronic Kidney Disease | COMPLETED | NCT01567085 |
| Placebo | Other | Phase PHASE2 | Delayed Function of Renal Transplant | TERMINATED | NCT01403389 |
| Eculizumab | Other | Phase PHASE2 | Delayed Function of Renal Transplant | TERMINATED | NCT01403389 |
| Placebo | Other | Phase PHASE2 | Delayed Function of Renal Transplant | TERMINATED | NCT01403389 |
| Eculizumab | Other | Phase PHASE2 | Delayed Function of Renal Transplant | TERMINATED | NCT01403389 |
| Placebo | Other | Phase PHASE3 | Refractory Generalized Myasthenia Gravis | COMPLETED | NCT01997229 |
| Eculizumab | Other | Phase PHASE3 | Refractory Generalized Myasthenia Gravis | COMPLETED | NCT01997229 |
| eculizumab | Other | Phase PHASE1 | Kidney; Complications, Allograft | COMPLETED | NCT01327573 |
| Eculizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT01194804 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis | TERMINATED | NCT00727194 |
| eculizumab | Other | Phase PHASE2 | Myasthenia Gravis | TERMINATED | NCT00727194 |
| Simeprevir | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT02512562 |
| ACH-3102 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT02512562 |
| AL-335 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT02512562 |
| Sebelipase Alfa | Other | Phase PHASE2 | Lysosomal Acid Lipase Deficiency | COMPLETED | NCT02112994 |
| ALXN1830 | Other | Phase PHASE1 | Pemphigus | TERMINATED | NCT03075904 |
| Placebo | Other | Phase PHASE3 | Refractory Generalized Myasthenia Gravis | COMPLETED | NCT02301624 |
| Eculizumab | Other | Phase PHASE3 | Refractory Generalized Myasthenia Gravis | COMPLETED | NCT02301624 |
| ALXN1830 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia | TERMINATED | NCT03075878 |
| asfotase alfa | Other | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT04189315 |
| Placebo | Other | Phase PHASE2 | Warm Autoimmune Hemolytic Anemia | WITHDRAWN | NCT04256148 |
| ALXN1830 | Other | Phase PHASE2 | Warm Autoimmune Hemolytic Anemia | WITHDRAWN | NCT04256148 |
| Standard of Care Medications | Drug | Preclinical | Wilson Disease | COMPLETED | NCT02763215 |
| Standard of Care Medications | Drug | Preclinical | Wilson Disease | COMPLETED | NCT02763215 |
| Placebo | Other | Phase PHASE3 | Lysosomal Acid Lipase Deficiency | COMPLETED | NCT01757184 |
| Sebelipase Alfa | Other | Phase PHASE3 | Lysosomal Acid Lipase Deficiency | COMPLETED | NCT01757184 |
| Placebo | Other | Phase PHASE3 | Lysosomal Acid Lipase Deficiency | COMPLETED | NCT01757184 |
| Sebelipase Alfa | Other | Phase PHASE3 | Lysosomal Acid Lipase Deficiency | COMPLETED | NCT01757184 |
| Ethinyl Estradiol/Norethindrone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Bupropion | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Warfarin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Digoxin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Midazolam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| ACH-0145228 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Digoxin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Midazolam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| ACH-0145228 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04451434 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04451434 |
| ACH126, 433 | Other | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT00040144 |
| Eculizumab | Other | Phase PHASE3 | Antibody-mediated Rejection | COMPLETED | NCT02013037 |
| Eculizumab | Other | Phase PHASE3 | Atypical Hemolytic Uremic | COMPLETED | NCT05876351 |
| No intervention | Other | Phase EARLY_PHASE1 | End Stage Liver Disease | WITHDRAWN | NCT03468140 |
| Eculizumab | Other | Phase EARLY_PHASE1 | End Stage Liver Disease | WITHDRAWN | NCT03468140 |
| No intervention | Other | Phase EARLY_PHASE1 | End Stage Liver Disease | WITHDRAWN | NCT03468140 |
| Eculizumab | Other | Phase EARLY_PHASE1 | End Stage Liver Disease | WITHDRAWN | NCT03468140 |
| Eculizumab | Other | Phase PHASE3 | Antibody-mediated Rejection | COMPLETED | NCT02013037 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04889690 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04889690 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04889690 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04889690 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04935294 |
| Mycophenolate Mofetil | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03108274 |
| Fexofenadine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03108274 |
| Midazolam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03108274 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03108274 |
| Danicopan - LFC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04940559 |
| Danicopan - Softgel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04940559 |
| Danicopan - Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04940559 |
| Danicopan | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03555539 |
| Danicopan Modified Release Prototype 3 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03384186 |
| Danicopan Modified Release Prototype 2 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03384186 |
| Danicopan Modified Release Prototype 1 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03384186 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| Danicopan-matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| Moxifloxacin-matching Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05047484 |
| ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05047484 |
| ALXN1840 | Other | Phase PHASE2 | Wilson Disease | COMPLETED | NCT02273596 |
| Eculizumab | Other | Preclinical | Covid19 | NO_LONGER_AVAILABLE | NCT04802083 |
| Danicopan | Other | Phase PHASE2 | C3 Glomerulonephritis | COMPLETED | NCT03124368 |
| Danicopan | Other | Phase PHASE2 | C3 Glomerulonephritis | COMPLETED | NCT03124368 |
| Omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Aluminum/Magnesium Hydroxide/Simethicone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Calcium Carbonate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Tacrolimus | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Cyclosporine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Aluminum/Magnesium Hydroxide/Simethicone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Calcium Carbonate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Tacrolimus | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Cyclosporine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Non contrast-enhanced magnetic resonance imaging | Other | Approved | C3 Glomerulonephritis | COMPLETED | NCT03723512 |
| ACH-0145228: Powder-in-capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04551586 |
| ACH-0145228: Immediate Release | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04551586 |
| Moxifloxacin-matching Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04660890 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04660890 |
| ALXN2050-matching Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04660890 |
| ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04660890 |
| Placebo | Other | Phase PHASE2 | Generalized Myasthenia Gravis | WITHDRAWN | NCT04982289 |
| ALXN1830 | Other | Phase PHASE2 | Generalized Myasthenia Gravis | WITHDRAWN | NCT04982289 |
| Placebo IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| Placebo SC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| rHuPH20 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| ALXN1720 IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| ALXN1720 SC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| Danicopan: Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04609696 |
| Danicopan: Powder-In-Capsule 2 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04609696 |
| Danicopan: Powder-In-Capsule 1 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04609696 |
| ALXN1210 | Other | Phase PHASE1 | PNH | COMPLETED | NCT02598583 |
| ALXN1210 | Other | Phase PHASE1 | PNH | COMPLETED | NCT02598583 |
| BSC | Other | Phase PHASE3 | COVID-19 Severe Pneumonia | TERMINATED | NCT04369469 |
| Ravulizumab | Other | Phase PHASE3 | COVID-19 Severe Pneumonia | TERMINATED | NCT04369469 |
| Danicopan | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03053102 |
| eculizumab | Other | Phase PHASE3 | Neuromyelitis Optica | COMPLETED | NCT02003144 |
| Placebo | Other | Phase PHASE2 | C3 Glomerulopathy | COMPLETED | NCT03369236 |
| Danicopan | Other | Phase PHASE2 | C3 Glomerulopathy | COMPLETED | NCT03369236 |
| Rifampin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04933682 |
| Fluconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04933682 |
| ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04933682 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04952545 |
| ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04952545 |
| Ravulizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT02605993 |
| Ravulizumab | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04248465 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04248465 |
| Danicopan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04551599 |
| [14C]-ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04609670 |
| [14C]-ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04609670 |
| ACH-0144471 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03181633 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03406507 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03406507 |
| MMF | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| Tacrolimus | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| Cyclosporine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| MMF | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| Tacrolimus | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| Cyclosporine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| ALXN2050 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05202145 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288829 |
| ALXN1210 IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288829 |
| ALXN1210 SC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288829 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288673 |
| ALXN1210 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288673 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288660 |
| ALXN1210 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288660 |
| ALXN1840 | Other | Preclinical | Wilson Disease | NO_LONGER_AVAILABLE | NCT05686564 |
| ALXN1840 | Other | Preclinical | Wilson Disease | NO_LONGER_AVAILABLE | NCT05686564 |
| No intervention | Other | Preclinical | PNH | COMPLETED | NCT05884060 |
| ALXN1720 | Other | Phase PHASE1 | Proteinuria | COMPLETED | NCT05314231 |
| Omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05319899 |
| ALXN1840 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05319899 |
| Omeprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05319912 |
| ALXN1840 Non-coated Capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05319912 |
| ALXN1840 Enteric-coated Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05319912 |
| ALXN1840 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05303324 |
| ALXN1840 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05303324 |
| ENB-0040 | Other | Phase PHASE2 | Hypophosphatasia | WITHDRAWN | NCT00894075 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04560816 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04560816 |
| ALXN1840 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04560816 |
| Emtricitabine | Other | Phase PHASE2 | Human Immunodeficiency Virus (HIV)-1 Infection | COMPLETED | NCT00380159 |
| Lamivudine | Other | Phase PHASE2 | Human Immunodeficiency Virus (HIV)-1 Infection | COMPLETED | NCT00380159 |
| Elvucitabine | Other | Phase PHASE2 | Human Immunodeficiency Virus (HIV)-1 Infection | COMPLETED | NCT00380159 |
| Celecoxib | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526197 |
| ALXN1840 | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526197 |
| Placebo | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01849562 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01849562 |
| ACH-3102 | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01849562 |
| Sovaprevir | Other | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01849562 |
| Ribavirin | Other | Phase PHASE1 | Chronic Hepatitis C Infection | COMPLETED | NCT01700179 |
| ACH-0143102 | Other | Phase PHASE1 | Chronic Hepatitis C Infection | COMPLETED | NCT01700179 |
| Ribavirin | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01180790 |
| Pegylated Interferon alpha-2a | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01180790 |
| Placebo | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01180790 |
| ACH-0141625 (Sovaprevir) | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01180790 |
| Efavirenz | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00350272 |
| Tenofovir | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00350272 |
| Lamivudine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00350272 |
| Elvucitabine | Other | Phase PHASE2 | HIV Infections | COMPLETED | NCT00350272 |
| Bupropion Hydrochloride | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526210 |
| ALXN1840 | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526210 |
| Bupropion Hydrochloride | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526210 |
| ALXN1840 | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526210 |
| ALXN2050 | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT04623710 |
| ALXN1840 | Other | Phase PHASE1 | Wilson Disease | COMPLETED | NCT05641311 |
| Eculizumab | Other | Phase PHASE2 | Preeclampsia | TERMINATED | NCT04725812 |
| Eculizumab | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03472885 |
| Danicopan | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03472885 |
| Betrixaban | Other | Phase PHASE1 | VTE Prophylaxis | TERMINATED | NCT03346083 |
| rHuPH20 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05396742 |
| Ravulizumab | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05396742 |
| ALXN1210 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05288816 |
| Ravulizumab | Other | Phase PHASE3 | Atypical Hemolytic Uremic Syndrome (aHUS) | COMPLETED | NCT02949128 |
| Ravulizumab | Other | Phase PHASE3 | Atypical Hemolytic Uremic Syndrome (aHUS) | COMPLETED | NCT03131219 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT05254613 |
| ALXN1830 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT05254613 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT02946463 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT02946463 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03920293 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03920293 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03920293 |
| Ravulizumab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | COMPLETED | NCT03920293 |
| ALXN2050 MR Prototype Mini-Tablet | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05780645 |
| ALXN2050 Immediate Release (IR) Tablet | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05780645 |
| ALXN2050 MR Prototype Tablet | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05780645 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05428696 |
| ALXN2080 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05428696 |
| SoC Therapy | Drug | Phase PHASE3 | Wilson Disease | TERMINATED | NCT03403205 |
| ALXN1840 | Other | Phase PHASE3 | Wilson Disease | TERMINATED | NCT03403205 |
| Carbamazepine (AxMP) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| Fluconazole (AxMP) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| ALXN2080 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| ALXN1840 | Other | Phase PHASE2 | Wilson Disease | COMPLETED | NCT04573309 |
| Usual Care | Other | Phase PHASE4 | Acute Intracranial Hemorrhage | COMPLETED | NCT03661528 |
| andexanet alfa | Other | Phase PHASE4 | Acute Intracranial Hemorrhage | COMPLETED | NCT03661528 |
| asfotase alfa | Other | Preclinical | Hypophosphatasia | COMPLETED | NCT04195763 |
| asfotase alfa | Other | Preclinical | Hypophosphatasia | COMPLETED | NCT04195763 |
| Placebo IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04631562 |
| Placebo SC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04631562 |
| ALXN1820 IV | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04631562 |
| ALXN1820 SC | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04631562 |
| Ravulizumab | Other | Phase PHASE4 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04320602 |
| Eculizumab | Other | Phase PHASE4 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04320602 |
| Ravulizumab | Other | Phase PHASE4 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04320602 |
| Eculizumab | Other | Phase PHASE4 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04320602 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT04730804 |
| ALXN1830 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT04730804 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03748823 |
| Ravulizumab OBDS | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT03748823 |
| Eculizumab | Other | Phase PHASE2 | Neuromyelitis Optica | TERMINATED | NCT04155424 |
| Eculizumab | Other | Phase PHASE2 | Neuromyelitis Optica | TERMINATED | NCT04155424 |
| Gefurulimab AI | Other | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT06208488 |
| Gefurulimab PFS-SD | Other | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT06208488 |
| Standard of Care | Other | Phase PHASE3 | Wilson Disease | TERMINATED | NCT05047523 |
| ALXN1840 | Other | Phase PHASE3 | Wilson Disease | TERMINATED | NCT05047523 |
| ALXN2050 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT04170023 |
| ALXN2050 | Other | Phase PHASE2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT04170023 |
| Placebo | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05751642 |
| ALXN1920 | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05751642 |
| Peripheral blood withdrawn | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT05419765 |
| Peripheral blood withdrawn | Other | Preclinical | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT05419765 |
| Eculizumab | Other | Phase PHASE3 | Myasthenia Gravis | COMPLETED | NCT03759366 |
| ALXN1850 | Other | Phase PHASE1 | Hypophosphatasia | COMPLETED | NCT04980248 |
| Acceptance and Commitment Therapy | Drug | Approved | NMO Spectrum Disorder | COMPLETED | NCT05840055 |
| Placebo | Other | Phase PHASE2 | Generalized Myasthenia Gravis | TERMINATED | NCT05218096 |
| ALXN2050 | Other | Phase PHASE2 | Generalized Myasthenia Gravis | TERMINATED | NCT05218096 |
| ALXN1820 | Other | Phase PHASE2 | Sickle Cell Disease (SCD) | TERMINATED | NCT05565092 |
| Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT02245867 |
| Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 | Other | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT02245867 |
| Treatment C | Drug | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT05578846 |
| Treatment B | Drug | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT05578846 |
| Treatment A | Drug | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT05578846 |
| Daratumumab | Other | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04304144 |
| SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) | Other | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04304144 |
| CAEL-101 | Other | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04304144 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03056040 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT03056040 |
| ALXN2050 | Other | Phase PHASE1 | Impaired Hepatic Function | TERMINATED | NCT05259085 |
| Eculizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05886244 |
| ALXN2080 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| Metformin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| ALXN2080 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| Metformin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| gefurulimab | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06677138 |
| C5 Inhibitor | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04469465 |
| Placebo | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04469465 |
| Danicopan | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04469465 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Ravulizumab | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT05274633 |
| Placebo | Other | Phase PHASE2 | Dermatomyositis | TERMINATED | NCT04999020 |
| Ravulizumab | Other | Phase PHASE2 | Dermatomyositis | TERMINATED | NCT04999020 |
| Ravulizumab | Other | Preclinical | Neuromyelitis Optica | RECRUITING | NCT06398158 |
| Placebo | Other | Phase PHASE2 | Geographic Atrophy | TERMINATED | NCT05019521 |
| Danicopan | Other | Phase PHASE2 | Geographic Atrophy | TERMINATED | NCT05019521 |
| Placebo | Other | Phase PHASE3 | Chronic Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT05778071 |
| eneboparatide | Other | Phase PHASE3 | Chronic Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT05778071 |
| Placebo | Other | Phase PHASE3 | Chronic Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT05778071 |
| eneboparatide | Other | Phase PHASE3 | Chronic Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT05778071 |
| Placebo | Other | Phase PHASE3 | Chronic Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT05778071 |
| eneboparatide | Other | Phase PHASE3 | Chronic Hypoparathyroidism | ACTIVE_NOT_RECRUITING | NCT05778071 |
| Ravulizumab | Other | Phase PHASE3 | Neuromyelitis Optica | COMPLETED | NCT04201262 |
| Ravulizumab | Other | Phase PHASE3 | Neuromyelitis Optica | COMPLETED | NCT04201262 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT05097989 |
| ALXN2050 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT05097989 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT05097989 |
| ALXN2050 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT05097989 |
| Eculizumab | Other | Phase PHASE1 | Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | WITHDRAWN | NCT02113891 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis, Active Moderate | TERMINATED | NCT01671956 |
| Bertilimumab | Other | Phase PHASE2 | Ulcerative Colitis, Active Moderate | TERMINATED | NCT01671956 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis, Active Moderate | TERMINATED | NCT01671956 |
| Bertilimumab | Other | Phase PHASE2 | Ulcerative Colitis, Active Moderate | TERMINATED | NCT01671956 |
| Bertilimumab | Other | Phase PHASE2 | Pemphigoid, Bullous | COMPLETED | NCT02226146 |
| Folic Acid | Other | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| IVIg | Other | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| bortezomib | Other | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| rituximab | Other | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| methotrexate | Other | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| ALXN2220 | Other | Phase PHASE2 | Amyloid Transthyretin Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT07213583 |
| eculizumab | Other | Phase PHASE3 | NMOSD | ACTIVE_NOT_RECRUITING | NCT06724809 |
| Acoramidis | Other | Phase PHASE4 | Transthyretin-type Cardiac Amyloidosis | RECRUITING | NCT07306949 |
| Acoramidis | Other | Phase PHASE4 | Transthyretin-type Cardiac Amyloidosis | RECRUITING | NCT07306949 |
| Best Supportive Care | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04557735 |
| Ravulizumab | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04557735 |
| Best Supportive Care | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04557735 |
| Ravulizumab | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04557735 |
| Ravulizumab | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT06578949 |
| Background Therapy | Drug | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT04564339 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT04564339 |
| Ravulizumab | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT04564339 |
| Ravulizumab | Other | Preclinical | Generalized Myasthenia Gravis | RECRUITING | NCT06967480 |
| Ravulizumab | Other | Preclinical | Generalized Myasthenia Gravis | RECRUITING | NCT06967480 |
| hLB-001 | Other | Preclinical | Methylmalonic Acidemia | ACTIVE_NOT_RECRUITING | NCT05506254 |
| Ultomiris | Other | Preclinical | Ultomiris-exposed Pregnant/ Postpartum | RECRUITING | NCT06312644 |
| Soliris/Ultomiris | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT07413250 |
| Danicopan | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT07413250 |
| Placebo | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079359 |
| ALXN1850 | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079359 |
| Placebo | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06183931 |
| ALXN2220 | Other | Phase PHASE3 | Transthyretin Amyloid Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT06183931 |
| Danicopan | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | AVAILABLE | NCT05982938 |
| Danicopan | Other | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | AVAILABLE | NCT05982938 |
| Acoramidis | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04958135 |
| Acoramidis | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04958135 |
| Acoramidis | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04958135 |
| asfotase alfa | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079372 |
| ALXN1850 | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079372 |
| Placebo | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079281 |
| ALXN1850 | Other | Phase PHASE3 | Hypophosphatasia | ACTIVE_NOT_RECRUITING | NCT06079281 |
| cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| Placebo | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| CAEL-101 | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| AZD0120 | Other | Phase PHASE1 | Relapsed AL Amyloidosis | RECRUITING | NCT07081646 |
| Placebo | Other | Phase PHASE2 | Antibody-Mediated Rejection | RECRUITING | NCT06744647 |
| ALXN2030 | Other | Phase PHASE2 | Antibody-Mediated Rejection | RECRUITING | NCT06744647 |
| Gefurulimab | Other | Phase PHASE3 | Generalized Myasthenia Gravis | RECRUITING | NCT06607627 |
| Tarperprumig | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| Placebo | Other | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| Placebo | Other | Phase PHASE2 | Acromegaly | RECRUITING | NCT07037420 |
| ALXN2420 | Other | Phase PHASE2 | Acromegaly | RECRUITING | NCT07037420 |
| Placebo | Other | Phase PHASE2 | Acromegaly | RECRUITING | NCT07037420 |
| ALXN2420 | Other | Phase PHASE2 | Acromegaly | RECRUITING | NCT07037420 |
| cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| Placebo | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| CAEL-101 | Other | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| Placebo | Other | Phase PHASE1 | Healthy Adult Participants | RECRUITING | NCT07352423 |
| ALXN2230 | Other | Phase PHASE1 | Healthy Adult Participants | RECRUITING | NCT07352423 |
| Placebo | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT05501717 |
| ALXN2030 | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT05501717 |
| Best supportive care | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04543591 |
| Placebo | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04543591 |
| Ravulizumab | Other | Phase PHASE3 | Thrombotic Microangiopathy | COMPLETED | NCT04543591 |
| Ravulizumab | Other | Phase PHASE3 | Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT05746559 |
| Placebo | Other | Phase PHASE3 | Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT05746559 |
| Ravulizumab | Other | Phase PHASE3 | Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT05746559 |
| Placebo | Other | Phase PHASE3 | Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT05746559 |
| Ultomiris | Other | Preclinical | Ultomiris-exposed Pregnant/ Postpartum | RECRUITING | NCT06312644 |
| Ultomiris | Other | Preclinical | Ultomiris-exposed Pregnant/ Postpartum | RECRUITING | NCT06312644 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | RECRUITING | NCT06291376 |
| Ravulizumab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy | RECRUITING | NCT06291376 |
| Danicopan | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05389449 |
| Danicopan | Other | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT05389449 |
| Ravulizumab | Other | Phase PHASE4 | aHUS | RECRUITING | NCT07308574 |
| Ravulizumab | Other | Phase PHASE4 | aHUS | RECRUITING | NCT07308574 |
| Placebo | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05556096 |
| ALXN1720 | Other | Phase PHASE3 | Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING | NCT05556096 |
| Placebo | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07157787 |
| ALXN1920 | Other | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07157787 |
| Sotagliflozin | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT02647918 |
| 1000 mg metformin | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01292993 |
| 400 mg LX4211 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01292993 |
| 300 mg LX4211 (liquid) | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01188863 |
| 300 mg LX4211 (50 mg tablets) | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01188863 |
| 300 mg LX4211 (150 mg tablets) | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01188863 |
| Schedule E | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule D | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule C | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule B | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule A | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Januvia® | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01441232 |
| LX4211 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01441232 |
| 250 mg tablets | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01411800 |
| 250 mg capsule | Other | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01411800 |
| Placebo | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 500 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 250 mg LX3305 BID | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 400 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 300 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 250 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 200 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 150 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 100 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 50 mg LX3305 QD | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| [14C]-LX4211 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01818232 |
| LX4211 Placebo | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555008 |
| LX4211 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01555008 |
| 500 mg [14C]-LX1606 | Other | Phase PHASE1 | Carcinoid Syndrome | COMPLETED | NCT01932528 |
| LX4211 Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01916863 |
| canagliflozin 300 mg | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01916863 |
| LX4211 400 mg | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01916863 |
| LX4211 Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01916850 |
| LX4211 800 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01916850 |
| LX4211 400 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01916850 |
| LX4211 Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01913002 |
| moxifloxacin 400 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01913002 |
| LX4211 2000 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01913002 |
| LX4211 800 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01913002 |
| Telotristat etiprate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02157584 |
| Telotristat etiprate | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02157558 |
| Fexofenadine | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02157558 |
| Moxifloxacin | Other | Phase PHASE1 | QT Interval | COMPLETED | NCT02155205 |
| Placebo | Other | Phase PHASE1 | QT Interval | COMPLETED | NCT02155205 |
| Telotristat etiprate | Other | Phase PHASE1 | QT Interval | COMPLETED | NCT02155205 |
| Midazolam | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02147808 |
| Telotristat etiprate | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02147808 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| 400 mg LX4211 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| 200 mg LX4211 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| 75 mg LX4211 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| Placebo tablet | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT01494233 |
| 250 mg LX1033 tablets | Other | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT01494233 |
| Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT02300363 |
| Treatment B (LX4211) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT02300363 |
| Treatment A (rosuvastatin) | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT02300363 |
| Treatment C Digoxin + 400 mg LX4211 administered concomitantly | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT02300350 |
| Treatment B LX4211 | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT02300350 |
| Treatment A digoxin | Drug | Phase PHASE1 | Healthy | COMPLETED | NCT02300350 |
| LX7101 Vehicle | Other | Phase PHASE1 | Primary Open-angle Glaucoma | COMPLETED | NCT01528111 |
| LX7101 (0.25%) | Other | Phase PHASE1 | Primary Open-angle Glaucoma | COMPLETED | NCT01528111 |
| LX7101 (0.125%) | Other | Phase PHASE1 | Primary Open-angle Glaucoma | COMPLETED | NCT01528111 |
| LX4211 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02373046 |
| oral contraceptive + sotagliflozin | Other | Phase PHASE1 | Healthy | UNKNOWN | NCT02494609 |
| oral contraceptive | Other | Phase PHASE1 | Healthy | UNKNOWN | NCT02494609 |
| sotagliflozin | Other | Phase PHASE1 | Healthy | UNKNOWN | NCT02494609 |
| Octreotide acetate | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02195635 |
| Telotristat etiprate | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02195635 |
| sotagliflozin | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT02471274 |
| Placebo | Other | Phase PHASE3 | Carcinoid Syndrome | COMPLETED | NCT02063659 |
| Telotristat etiprate | Other | Phase PHASE3 | Carcinoid Syndrome | COMPLETED | NCT02063659 |
| Placebo-matching telotristat etiprate | Other | Phase PHASE3 | Carcinoid Syndrome | COMPLETED | NCT01677910 |
| Telotristat etiprate | Other | Phase PHASE3 | Carcinoid Syndrome | COMPLETED | NCT01677910 |
| Telotristat ethyl 250 mg | Other | Phase PHASE1 | Drug-drug Interaction | COMPLETED | NCT03302845 |
| Famotidine 40 mg | Other | Phase PHASE1 | Drug-drug Interaction | COMPLETED | NCT03302845 |
| Omeprazole 40 MG | Other | Phase PHASE1 | Drug-drug Interaction | COMPLETED | NCT03302845 |
| Telotristat Ethyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03423446 |
| Telotristat etiprate | Other | Phase PHASE2 | Carcinoid Syndrome | COMPLETED | NCT01104415 |
| Placebo | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01456052 |
| Telotristat Etiprate | Other | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01456052 |
| Telotristat etiprate | Other | Phase PHASE3 | Carcinoid Syndrome | COMPLETED | NCT02026063 |
| telotristat ethyl | Other | Preclinical | Pancreatic Cancer | WITHDRAWN | NCT04034745 |
| Volagidemab | Other | Phase PHASE1 | Type 1 Diabetes | RECRUITING | NCT05696366 |
| Sotagliflozin | Other | Phase PHASE1 | Type 1 Diabetes | RECRUITING | NCT05696366 |
| LX9211 Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathy | COMPLETED | NCT04455633 |
| LX9211 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathy | COMPLETED | NCT04455633 |
| Eliquis followed by 3 drugs in a random order | Drug | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Clopidogrel followed by 3 drugs in a random order | Drug | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Aspirin followed by 3 drugs in a random order | Drug | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Sotagliflozin (SOTA) followed by 3 drugs in a random order | Drug | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT06435156 |
| Sotagliflozin | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT06435156 |
| LX9211 (blinded) | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | COMPLETED | NCT06203002 |
| Placebo (blinded) | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | COMPLETED | NCT06203002 |
| Telotristat Ethyl | Other | Phase PHASE2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | COMPLETED | NCT03910387 |
| Nab-paclitaxel | Other | Phase PHASE2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | COMPLETED | NCT03910387 |
| Gemcitabine | Other | Phase PHASE2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | COMPLETED | NCT03910387 |
| LX9211 | Other | Phase PHASE2 | Postherpetic Neuralgia | COMPLETED | NCT04662281 |
| Placebo | Other | Phase PHASE2 | Postherpetic Neuralgia | COMPLETED | NCT04662281 |
| Placebo | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| Sotagliflozin | Other | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| AZD0120 | DRUG | Phase PHASE1 | Relapsed AL Amyloidosis | RECRUITING | NCT07081646 |
| Ravulizumab | DRUG | Phase PHASE3 | Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT05746559 |
| Placebo | DRUG | Phase PHASE3 | Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | NCT05746559 |
| Eculizumab (Soliris®) | DRUG | Phase PHASE2 | Shiga-like Toxin-producing Escherichia Coli | COMPLETED | NCT01410916 |
| enzyme analysis | OTHER | Approved | Lysosomal Acid Lipase Deficiency | UNKNOWN | NCT01716728 |
| ALXN1103 | DRUG | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT01335165 |
| ALXN1102 | DRUG | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | TERMINATED | NCT01335165 |
| ACH126-443 (Beta-L-Fd4C) | DRUG | Phase PHASE2 | HIV Infections | TERMINATED | NCT00040157 |
| ALXN1007 | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01883544 |
| Standard of care treatment | DRUG | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | WITHDRAWN | NCT01275287 |
| pexelizumab | DRUG | Phase PHASE3 | Cardio-pulmonary Bypass | COMPLETED | NCT00048308 |
| Saline | DRUG | Phase PHASE2 | Age-Related Macular Degeneration | COMPLETED | NCT00935883 |
| There is no intervention in the study | OTHER | Preclinical | Lysosomal Acid Lipase Deficiency | TERMINATED | NCT02926872 |
| Study Drug- ALXN1007 | BIOLOGICAL | Phase PHASE2 | Antiphospholipid (aPL)-Positive | TERMINATED | NCT02128269 |
| Plasmapheresis | PROCEDURE | Phase PHASE2 | Antibody-mediated Rejection | TERMINATED | NCT01895127 |
| Immunoglobulin | BIOLOGICAL | Phase PHASE2 | Antibody-mediated Rejection | TERMINATED | NCT01895127 |
| pexelizumab in conjunction with CABG | DRUG | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00088179 |
| Normal Saline | DRUG | Phase PHASE2 | Delayed Graft Function | TERMINATED | NCT01919346 |
| Samalizumab | DRUG | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT02987504 |
| sebelipase alfa | DRUG | Preclinical | Lysosomal Acid Lipase Deficiency | NO_LONGER_AVAILABLE | NCT02376751 |
| SBC-103 | DRUG | Phase PHASE1 | Mucopolysaccharidosis III, Type B (MPS IIIB) | TERMINATED | NCT02618512 |
| Sebelipase alfa 3 mg/kg | DRUG | Phase PHASE1 | Cholesterol Ester Storage Disease(CESD) | COMPLETED | NCT01307098 |
| Sebelipase alfa 1 mg/kg | DRUG | Phase PHASE1 | Cholesterol Ester Storage Disease(CESD) | COMPLETED | NCT01307098 |
| Sebelipase alfa 0.35 mg/kg | DRUG | Phase PHASE1 | Cholesterol Ester Storage Disease(CESD) | COMPLETED | NCT01307098 |
| ALXN1007 20 mg/kg twice weekly | BIOLOGICAL | Phase PHASE2 | Acute Graft-Versus-Host Disease | TERMINATED | NCT02245412 |
| ALXN1007 20 mg/kg once weekly | BIOLOGICAL | Phase PHASE2 | Acute Graft-Versus-Host Disease | TERMINATED | NCT02245412 |
| ALXN1007 10 mg/kg once weekly | BIOLOGICAL | Phase PHASE2 | Acute Graft-Versus-Host Disease | TERMINATED | NCT02245412 |
| Sebelipase alfa (SBC-102) | DRUG | Phase PHASE2 | Lysosomal Acid Lipase Deficiency | COMPLETED | NCT01371825 |
| Retrospective Case Only | BIOLOGICAL | Preclinical | Hypophosphatasia | COMPLETED | NCT02235493 |
| Asfotase alfa | DRUG | Phase PHASE2 | Hypophosphatasia | COMPLETED | NCT02797821 |
| Simeprevir | DRUG | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT02512562 |
| AL-335 | DRUG | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT02512562 |
| Standard of Care Medications | DRUG | Preclinical | Wilson Disease | COMPLETED | NCT02763215 |
| Sebelipase Alfa | DRUG | Phase PHASE2 | Lysosomal Acid Lipase Deficiency | TERMINATED | NCT02193867 |
| Ethinyl Estradiol/Norethindrone | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Bupropion | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Warfarin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| Digoxin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| ACH-0145228 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| ACH126, 433 | DRUG | Phase PHASE2 | Chronic Hepatitis B | TERMINATED | NCT00040144 |
| ACH-126,443 | DRUG | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT00034359 |
| [14C]-Danicopan | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04889391 |
| Mycophenolate Mofetil | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03108274 |
| Danicopan - LFC | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04940559 |
| Danicopan - Softgel | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04940559 |
| Danicopan - Tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04940559 |
| Danicopan Modified Release Prototype 3 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03384186 |
| Danicopan Modified Release Prototype 2 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03384186 |
| Danicopan Modified Release Prototype 1 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03384186 |
| Danicopan-matching placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| Aluminum/Magnesium Hydroxide/Simethicone | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Calcium Carbonate | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Tacrolimus | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Cyclosporine | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| Non contrast-enhanced magnetic resonance imaging | DEVICE | Approved | C3 Glomerulonephritis | COMPLETED | NCT03723512 |
| ACH-0145228: Powder-in-capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04551586 |
| ACH-0145228: Immediate Release | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04551586 |
| Moxifloxacin-matching Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| ALXN2050-matching Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04660890 |
| ALXN1720 IV | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| ALXN1720 SC | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| Andexanet | BIOLOGICAL | Phase PHASE3 | Bleeding | COMPLETED | NCT02329327 |
| Rituximab | BIOLOGICAL | Phase PHASE1 | Follicular Lymphoma (FL/Indolent NHL) | COMPLETED | NCT01994382 |
| Cerdulatinib | DRUG | Phase PHASE1 | Follicular Lymphoma (FL/Indolent NHL) | COMPLETED | NCT01994382 |
| Danicopan: Tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04609696 |
| Danicopan: Powder-In-Capsule 2 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04609696 |
| Danicopan: Powder-In-Capsule 1 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04609696 |
| BSC | OTHER | Phase PHASE3 | COVID-19 Severe Pneumonia | TERMINATED | NCT04369469 |
| ACH-0137171 | DRUG | Phase PHASE2 | HCV Infection | TERMINATED | NCT00401947 |
| Rifampin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04933682 |
| Fluconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04933682 |
| [14C]-ALXN2050 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04609670 |
| ALXN2040 | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05708573 |
| ALXN1210 IV | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05288829 |
| ALXN1210 SC | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05288829 |
| No intervention | OTHER | Phase EARLY_PHASE1 | End Stage Liver Disease | WITHDRAWN | NCT03468140 |
| Omeprazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05109390 |
| ALXN1840 Non-coated Capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05319912 |
| ALXN1840 Enteric-coated Tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05319912 |
| ENB-0040 | BIOLOGICAL | Phase PHASE2 | Hypophosphatasia | WITHDRAWN | NCT00894075 |
| Emtricitabine | DRUG | Phase PHASE2 | Human Immunodeficiency Virus (HIV)-1 Infection | COMPLETED | NCT00380159 |
| Celecoxib | DRUG | Phase PHASE1 | Wilson Disease | COMPLETED | NCT04526197 |
| ACH-3102 | DRUG | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT02512562 |
| Sovaprevir | DRUG | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01849562 |
| ACH-0143102 | DRUG | Phase PHASE1 | Chronic Hepatitis C Infection | COMPLETED | NCT01700179 |
| Ribavirin | DRUG | Phase PHASE2 | Hepatitis C, Chronic | COMPLETED | NCT01849562 |
| Pegylated Interferon alpha-2a | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01180790 |
| ACH-0141625 (Sovaprevir) | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT01180790 |
| Efavirenz | DRUG | Phase PHASE2 | HIV Infections | COMPLETED | NCT00350272 |
| Tenofovir | DRUG | Phase PHASE2 | HIV Infections | COMPLETED | NCT00350272 |
| Lamivudine | DRUG | Phase PHASE2 | Hepatitis B, Chronic | COMPLETED | NCT00034359 |
| Elvucitabine | DRUG | Phase PHASE2 | HIV Infections | COMPLETED | NCT00675844 |
| Betrixaban | DRUG | Phase PHASE1 | VTE Prophylaxis | TERMINATED | NCT03346083 |
| rHuPH20 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| ALXN1210 | BIOLOGICAL | Phase PHASE1 | PNH | COMPLETED | NCT02598583 |
| cerdulatinib | DRUG | Preclinical | Relapsed/Refractory Chronic Lymphocytic Leukemia | NO_LONGER_AVAILABLE | NCT04757259 |
| ALXN2050 MR Prototype Mini-Tablet | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05780645 |
| ALXN2050 Immediate Release (IR) Tablet | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05780645 |
| ALXN2050 MR Prototype Tablet | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05780645 |
| SoC Therapy | DRUG | Phase PHASE3 | Wilson Disease | TERMINATED | NCT03403205 |
| Carbamazepine (AxMP) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| Fluconazole (AxMP) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| Itraconazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| Usual Care | DRUG | Phase PHASE4 | Acute Intracranial Hemorrhage | COMPLETED | NCT03661528 |
| andexanet alfa | DRUG | Phase PHASE2 | Surgery | TERMINATED | NCT04233073 |
| ALXN1840 | DRUG | Phase PHASE2 | Wilson Disease | COMPLETED | NCT02273596 |
| Placebo IV | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| Placebo SC | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04920370 |
| ALXN1820 IV | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04631562 |
| ALXN1820 SC | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04631562 |
| ALXN1830 | DRUG | Phase PHASE1 | Pemphigus | TERMINATED | NCT03075904 |
| Best Supportive Care | OTHER | Phase PHASE3 | Thrombotic Microangiopathy | TERMINATED | NCT04743804 |
| Bis-Choline Tetrathiomolybdate | DRUG | Phase PHASE2 | Wilson Disease | COMPLETED | NCT04422431 |
| Gefurulimab AI | DRUG | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT06208488 |
| Gefurulimab PFS-SD | DRUG | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT06208488 |
| BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations | DRUG | Phase PHASE1 | Diffuse Intrinsic Pontine Glioma | TERMINATED | NCT04771897 |
| BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance | DRUG | Phase PHASE1 | Diffuse Intrinsic Pontine Glioma | TERMINATED | NCT04771897 |
| Acceptance and Commitment Therapy | BEHAVIORAL | Approved | NMO Spectrum Disorder | COMPLETED | NCT05840055 |
| ALXN1820 | DRUG | Phase PHASE2 | Sickle Cell Disease (SCD) | TERMINATED | NCT05565092 |
| BXQ-350 | DRUG | Phase PHASE1 | Neoplasms | TERMINATED | NCT03967093 |
| Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 | DRUG | Phase PHASE1 | AL Amyloidosis | COMPLETED | NCT02245867 |
| Treatment C | DRUG | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT05578846 |
| Treatment B | DRUG | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT05578846 |
| Treatment A | DRUG | Phase PHASE1 | Healthy Adult Participants | COMPLETED | NCT05578846 |
| ALXN1910 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05307978 |
| Daratumumab | DRUG | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04304144 |
| SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) | DRUG | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04304144 |
| ALXN2080 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06173596 |
| gefurulimab | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06677138 |
| C5 Inhibitor | DRUG | Phase PHASE3 | Paroxysmal Nocturnal Hemoglobinuria | COMPLETED | NCT04469465 |
| Carbamazepine | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06071442 |
| Levonorgestrel / Ethinyl Estradiol | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06071442 |
| Rosuvastatin | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT05708573 |
| Vemircopan | DRUG | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06071442 |
| AZP-3601 | DRUG | Phase PHASE1 | Chronic Hypoparathyroidism | COMPLETED | NCT05239221 |
| ALXN2050 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05047484 |
| Bertilimumab | BIOLOGICAL | Phase PHASE2 | Ulcerative Colitis, Active Moderate | TERMINATED | NCT01671956 |
| Folic Acid | DRUG | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| IVIg | DRUG | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| bortezomib | DRUG | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| rituximab | DRUG | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| methotrexate | DRUG | Phase PHASE4 | Hypophosphatasia | WITHDRAWN | NCT06015750 |
| eculizumab | DRUG | Preclinical | Hemoglobinuria, Paroxysmal | APPROVED_FOR_MARKETING | NCT00438789 |
| Eculizumab | DRUG | Phase PHASE1 | Neuromyelitis Optica | COMPLETED | NCT00904826 |
| ALXN2230 | DRUG | Phase PHASE1 | Healthy Adult Participants | NOT_YET_RECRUITING | NCT07352423 |
| hLB-001 | BIOLOGICAL | Phase PHASE1 | Methylmalonic Acidemia | TERMINATED | NCT04581785 |
| Asfotase Alfa | BIOLOGICAL | Phase PHASE4 | Hypophosphatasia | COMPLETED | NCT02531867 |
| Soliris/Ultomiris | DRUG | Preclinical | Paroxysmal Nocturnal Hemoglobinuria | ACTIVE_NOT_RECRUITING | NCT07413250 |
| ALXN2220 | DRUG | Phase PHASE2 | Amyloid Transthyretin Cardiomyopathy | ACTIVE_NOT_RECRUITING | NCT07213583 |
| Prednisone/Prednisolone | DRUG | Phase PHASE4 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07221838 |
| Oral Corticosteroid Tapering Schedule | PROCEDURE | Phase PHASE4 | Generalized Myasthenia Gravis | NOT_YET_RECRUITING | NCT07221838 |
| ALXN1920 | DRUG | Phase PHASE2 | Primary Membranous Nephropathy | RECRUITING | NCT07157787 |
| ALXN2350 | DRUG | Phase PHASE1 | BAG3 Mutation Associated Dilated Cardiomyopathy | RECRUITING | NCT07218887 |
| asfotase alfa | BIOLOGICAL | Phase PHASE2 | Hypophosphatasia | COMPLETED | NCT01205152 |
| ALXN1850 | BIOLOGICAL | Phase PHASE1 | Hypophosphatasia | COMPLETED | NCT04980248 |
| cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen | DRUG | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04504825 |
| Best supportive care | OTHER | Phase PHASE3 | Thrombotic Microangiopathy | ACTIVE_NOT_RECRUITING | NCT04543591 |
| ALXN2030 | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT05501717 |
| Tarperprumig | DRUG | Phase PHASE2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | RECRUITING | NCT07160608 |
| ALXN2420 | DRUG | Phase PHASE2 | Acromegaly | RECRUITING | NCT07037420 |
| Ravulizumab | BIOLOGICAL | Phase PHASE3 | COVID-19 Severe Pneumonia | TERMINATED | NCT04369469 |
| Danicopan | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709094 |
| cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen | DRUG | Phase PHASE3 | AL Amyloidosis | ACTIVE_NOT_RECRUITING | NCT04512235 |
| CAEL-101 | DRUG | Phase PHASE2 | AL Amyloidosis | COMPLETED | NCT04304144 |
| Metformin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT06160414 |
| Dual Continuous Glucose and Ketone Monitor | DEVICE | Phase PHASE3 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07211802 |
| Sotagliflozin High Dose | DRUG | Phase PHASE3 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07211802 |
| Sotagliflozin Low Dose | DRUG | Phase PHASE3 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07211802 |
| Eliquis followed by 3 drugs in a random order | DRUG | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Clopidogrel followed by 3 drugs in a random order | DRUG | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Aspirin followed by 3 drugs in a random order | DRUG | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| Sotagliflozin (SOTA) followed by 3 drugs in a random order | DRUG | Phase EARLY_PHASE1 | Platelet Function and Reactivity Tests | RECRUITING | NCT06933056 |
| LX9211 (blinded) | DRUG | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | COMPLETED | NCT06203002 |
| Placebo (blinded) | DRUG | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | COMPLETED | NCT06203002 |
| Ambrisentan and Sotagliflozin | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus With Diabetic Nephropathy | NOT_YET_RECRUITING | NCT06072326 |
| Ambrisentan | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus With Diabetic Nephropathy | NOT_YET_RECRUITING | NCT06072326 |
| Volagidemab | DRUG | Phase PHASE1 | Type 1 Diabetes | RECRUITING | NCT05696366 |
| LX9211 Matching Placebo | DRUG | Phase PHASE2 | Diabetic Peripheral Neuropathy | COMPLETED | NCT04455633 |
| LX9211 | DRUG | Phase PHASE2 | Postherpetic Neuralgia | COMPLETED | NCT04662281 |
| telotristat ethyl | DRUG | Preclinical | Pancreatic Cancer | WITHDRAWN | NCT04034745 |
| Nab-paclitaxel | DRUG | Phase PHASE2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | COMPLETED | NCT03910387 |
| Gemcitabine | DRUG | Phase PHASE2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | COMPLETED | NCT03910387 |
| Telotristat Ethyl | DRUG | Phase PHASE2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | COMPLETED | NCT03910387 |
| Telotristat ethyl 250 mg | DRUG | Phase PHASE1 | Drug-drug Interaction | COMPLETED | NCT03302845 |
| Famotidine 40 mg | DRUG | Phase PHASE1 | Drug-drug Interaction | COMPLETED | NCT03302845 |
| Omeprazole 40 MG | DRUG | Phase PHASE1 | Drug-drug Interaction | COMPLETED | NCT03302845 |
| Sotagliflozin | DRUG | Phase PHASE3 | Obstructive Cardiomyopathy, Hypertrophic | RECRUITING | NCT06481891 |
| oral contraceptive + sotagliflozin | DRUG | Phase PHASE1 | Healthy | UNKNOWN | NCT02494609 |
| oral contraceptive | DRUG | Phase PHASE1 | Healthy | UNKNOWN | NCT02494609 |
| sotagliflozin | DRUG | Phase PHASE1 | Healthy | UNKNOWN | NCT02494609 |
| Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02300363 |
| Treatment B (LX4211) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02300363 |
| Treatment A (rosuvastatin) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02300363 |
| Treatment C Digoxin + 400 mg LX4211 administered concomitantly | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02300350 |
| Treatment B LX4211 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02300350 |
| Treatment A digoxin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02300350 |
| Octreotide acetate | DRUG | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02195635 |
| Fexofenadine | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03108274 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05016206 |
| Midazolam | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04709081 |
| 500 mg [14C]-LX1606 | DRUG | Phase PHASE1 | Carcinoid Syndrome | COMPLETED | NCT01932528 |
| canagliflozin 300 mg | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01916863 |
| LX4211 400 mg | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01916863 |
| moxifloxacin 400 mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01913002 |
| LX4211 2000 mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01913002 |
| LX4211 800 mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01916850 |
| [14C]-LX4211 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01818232 |
| Placebo-matching telotristat etiprate | DRUG | Phase PHASE3 | Carcinoid Syndrome | COMPLETED | NCT01677910 |
| LX4211 Placebo | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT01916863 |
| LX7101 Vehicle | DRUG | Phase PHASE1 | Primary Open-angle Glaucoma | COMPLETED | NCT01528111 |
| LX7101 (0.25%) | DRUG | Phase PHASE1 | Primary Open-angle Glaucoma | COMPLETED | NCT01528111 |
| LX7101 (0.125%) | DRUG | Phase PHASE1 | Primary Open-angle Glaucoma | COMPLETED | NCT01528111 |
| Placebo tablet | DRUG | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT01494233 |
| 250 mg LX1033 tablets | DRUG | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT01494233 |
| Telotristat Etiprate | DRUG | Phase PHASE2 | Ulcerative Colitis | COMPLETED | NCT01456052 |
| Januvia® | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01441232 |
| LX4211 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02373046 |
| 500 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 250 mg LX3305 BID | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 400 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 300 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 250 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 200 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 150 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 100 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 50 mg LX3305 QD | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT01417052 |
| 250 mg tablets | DRUG | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01411800 |
| 250 mg capsule | DRUG | Phase PHASE1 | Irritable Bowel Syndrome | COMPLETED | NCT01411800 |
| 200 mg LX4211 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| 75 mg LX4211 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| Schedule E | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule D | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule C | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule B | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| Schedule A | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01334242 |
| 1000 mg metformin | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01292993 |
| 400 mg LX4211 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT01376557 |
| 300 mg LX4211 (liquid) | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01188863 |
| 300 mg LX4211 (50 mg tablets) | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01188863 |
| 300 mg LX4211 (150 mg tablets) | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01188863 |
| LX4211 High Dose | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00962065 |
| LX4211 Low Dose | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00962065 |
| LX3305 high dose | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00903383 |
| LX3305 mid dose | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00903383 |
| LX3305 low dose | DRUG | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00903383 |
| Octreotide LAR Depot | DRUG | Phase PHASE2 | Carcinoid Syndrome | COMPLETED | NCT00853047 |
| Telotristat etiprate | DRUG | Phase PHASE1 | Drug Interactions | COMPLETED | NCT02195635 |
| Methotrexate | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00847886 |
| LX3305 Placebo | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00847886 |
| LX3305 | DRUG | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00847886 |
| LX1031 Low Dose | DRUG | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00813098 |
| LX1031 High Dose | DRUG | Phase PHASE2 | Irritable Bowel Syndrome | COMPLETED | NCT00813098 |
| Placebo | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT01454986 |
| LX6171 Low Dose | DRUG | Phase PHASE2 | Age-Related Memory Disorders | COMPLETED | NCT00691808 |
| LX6171 High Dose | DRUG | Phase PHASE2 | Age-Related Memory Disorders | COMPLETED | NCT00691808 |
Total products: 890